{| class="wikitable" style="text-align:center; width:100%;"
! style="color:white; font-size:125%; background-color:#08519c" align="center" colspan="4" |'''Section editors'''
|-
| style="background-color:#F0F0F0; width:15%" |[[File:nkv.jpg|frameless|upright=0.3|center]]
| style="width:35%" |<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>Chicago, IL</big>
| style="background-color:#F0F0F0; width:15%" |[[File:TravisOsterman.jpg|frameless|upright=0.3|center]]
| style="width:35%" |<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn]
|-
|}
{| class="wikitable" style="text-align:center; width:50%;"
! style="color:white; font-size:125%; background-color:#08519c" align="center" colspan="2" |'''Page editor'''
|-
| style="background-color:#F0F0F0; width:30%" |[[File:Naina Singh.JPG|frameless|upright=0.3|center]]
|<big>[[User:Nainasingh|Naina Singh, MD]]<br>Chicago, IL</big>
|-
|}
'''Please be aware that some regimens listed here are studies for [[gastric cancer]], not esophageal cancer,''' reflecting the overlap between treatments of esophageal and gastric cancer.

{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==CAP/ASCP/ASCO==
*'''2017:''' Bartley et al. [http://ascopubs.org/doi/full/10.1200/JCO.2016.69.4836 HER2 testing and clinical decision making in gastroesophageal adenocarcinoma] [https://www.ncbi.nlm.nih.gov/pubmed/28129524 PubMed]

==[http://www.esmo.org/ ESMO]==
*'''2016:''' Lordick et al. [https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Oesophageal-Cancer Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf NCCN Guidelines - Esophageal and Esophagogastric Junction Cancers]

=Neoadjuvant induction therapy=
==Cisplatin & Docetaxel {{#subobject:eed8f6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:523945|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/20/9/1522.long Ruhstaller et al. 2009 (SAKK 75/02)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://academic.oup.com/annonc/article/29/6/1386/4959906 Ruhstaller et al. 2018 (SAKK 75/08)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin, Docetaxel, Cetuximab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''SAKK 75/02 patients: 55% adenocarcinoma, 45% squamous cell histology''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#Cisplatin.2C_Docetaxel.2C_RT|Neoadjuvant cisplatin, docetaxel, RT]], then [[Surgery#Esophageal_cancer_surgery|surgery]]

===References===
# '''SAKK 75/02:''' Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, Köberle D, Terraciano L, Schnider A, Bodis S, Popescu R; Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol. 2009 Sep;20(9):1522-8. Epub 2009 May 22. [http://annonc.oxfordjournals.org/content/20/9/1522.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19465425 PubMed]
# '''SAKK 75/08:''' Ruhstaller T, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A, Plasswilm L, Budach W, Eisterer W, Hawle H, Mariette C, Hess V, Mingrone W, Montemurro M, Girschikofsky M, Schmidt SC, Bitzer M, Bedenne L, Brauchli P, Stahl M; Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol. 2018 Jun 1;29(6):1386-1393. [https://academic.oup.com/annonc/article/29/6/1386/4959906 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29635438 PubMed]

==Cisplatin & Etoposide {{#subobject:5a71ff|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f93c95|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123658/ Boonstra et al. 2011]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Patients: 100% squamous cell histology''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 4 hours once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup>/day IV over 2 hours once on days 1 & 2, then 200 mg/m<sup>2</sup>/day PO once per day on days 3 & 5

'''21-day cycle for 2 to 4 cycles'''
====Subsequent treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]]
===References===
# Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, Siersema PD, Dinjens WN, van Lanschot JJ, Tilanus HW, van der Gaast A. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011 May 19;11:181. [https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-181 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123658/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21595951 PubMed]

==Cisplatin & Fluorouracil {{#subobject:37e6ba|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
<br>FP: '''<u>F</u>'''luorouracil, '''<u>P</u>'''latinol (Cisplatin)
===Variant #1, 40/4200 {{#subobject:034277|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/24/3953.long Ajani et al. 2006 (RTOG 9904)]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% adenocarcinoma histology. The majority of patients had gastric adenocarcinoma. Although gastroesophageal junction was involved, percentages were not included.''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 & 5
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>)

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#Fluorouracil.2C_Paclitaxel.2C_RT|Neoadjuvant fluorouracil, paclitaxel, RT]], then [[Surgery#Esophageal_cancer_surgery|surgery]]

===Variant #2, 80/4000, 4 day 5-FU infusion {{#subobject:2335c3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08651-8/fulltext Girling et al. 2002 (UK MRC OE02)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585417/ Alderson et al. 2017 (UK MRC OE05)]
| style="background-color:#1a9851" |Phase III (C)
|[[#ECX|ECX]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: efficacy for UK MRC OE02 is based on the 2009 update.''
''UK MRC OE05 patients: 100% adenocarcinoma of the esophagus (including Siewert types 1 and 2 gastroesophageal junction tumors)''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]]

===Variant #3, 80/4000, 5 day 5-FU infusion {{#subobject:4b5879|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1245%2Fs10434-011-2049-9 Ando et al. 2011 (JCOG 9907)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Fluorouracil_3|Adjuvant CF]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]]

===Variant #4, 100/4000 {{#subobject:ac1485|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.0597 Ychou et al. 2011 (ACCORD 07)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''This is the neoadjuvant portion of pre-planned perioperative chemotherapy. It is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''

''Patients: 100% adenocarcinoma histology (65% esophagogastric junction, 10% lower esophageal, 25% gastric adenocarcinoma)''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''28-day cycle for 2 or 3 cycles'''
====Subsequent treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]], then [[#Cisplatin_.26_Fluorouracil_3|adjuvant CF]]

===Variant #5, 100/5000 {{#subobject:e6fe90|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199812313392704 Kelsen et al. 1998 (RTOG 8911)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142%2820010601%2991%3A11%3C2165%3A%3AAID-CNCR1245%3E3.0.CO%3B2-H Ancona et al. 2001]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: it is not entirely clear from Ancona et al. 2001 whether this was a 96-hour or 120-hour infusion; there was option to proceed after the 2nd cycle. In both trials, this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority.''

''Ancona et al. 2001 patients: 100% squamous cell carcinoma histology''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: see note)

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*RTOG 8911: [[Surgery#Esophageal_cancer_surgery|Surgery]], then [[#Cisplatin_.26_Fluorouracil_3|adjuvant CF]]
*Ancona et al. 2001: [[Surgery#Esophageal_cancer_surgery|Surgery]], performed 3 to 4 weeks after the last cycle of chemotherapy
===References===
# '''RTOG 8911:''' Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31;339(27):1979-84. [https://www.nejm.org/doi/full/10.1056/NEJM199812313392704 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9869669 PubMed]
## '''Update:''' Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG; Radiation Therapy Oncology Group; USA Intergroup. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007 Aug 20;25(24):3719-25. [http://ascopubs.org/doi/full/10.1200/JCO.2006.10.4760 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17704421 PubMed]
# Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001 Jun 1;91(11):2165-74. [https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142%2820010601%2991%3A11%3C2165%3A%3AAID-CNCR1245%3E3.0.CO%3B2-H link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11391598 PubMed]
# '''UK MRC OE02:''' Girling DJ, Bancewicz J, Clark PI, Smith DB, Donnelly RJ, Fayers PM, Weeden S, Hutchinson T, Harvey A, Lyddiard J; Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1727-33. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08651-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12049861 PubMed]
## '''Update:''' Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009 Oct 20;27(30):5062-7. Epub 2009 Sep 21. [http://ascopubs.org/doi/full/10.1200/JCO.2009.22.2083 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19770374 PubMed]
# '''RTOG 9904:''' Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006 Aug 20;24(24):3953-8. [http://jco.ascopubs.org/content/24/24/3953.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16921048 PubMed]
# '''ACCORD 07:''' Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. Epub 2011 Mar 28. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.0597 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21444866 PubMed]
# '''JCOG 9907:''' Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012 Jan;19(1):68-74. Epub 2011 Aug 31. [https://link.springer.com/article/10.1245%2Fs10434-011-2049-9 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21879261 PubMed]
# '''UK MRC OE05:''' Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1249-1260. Epub 2017 Aug 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30447-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585417/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28784312 PubMed]

==Cisplatin & Irinotecan {{#subobject:500b44|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:927613|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.redjournal.org/article/S0360-3016(09)00362-9/abstract Rivera et al. 2009]
| style="background-color:#91cf61" |Phase II
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.26591/full Ilson et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
''Rivera et al. patients: 100% adenocarcinoma histology (43% gastroesophageal junction, 57% gastric adenocarcinoma)''

''Illson et al. patients: 75% adenocarcinoma, 22% squamous cell, 3% poorly differentiated history; 33% gastroesophageal junction.''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8, '''given first'''
*[[Irinotecan (Camptosar)]] 65 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8, '''given second'''

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV or PO prior to chemotherapy
*[[Granisetron]] 2 mg PO or [[Ondansetron (Zofran)]] 32 mg IV prior to chemotherapy
*At least 500 mL D5NS or NS as supportive hydration
*[[Atropine (Atropen)]] 0.5 to 1 mg IV prn cholinergic symptoms

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#Cisplatin.2C_Irinotecan.2C_RT|Neoadjuvant cisplatin, irinotecan, RT]], then [[Surgery#Esophageal_cancer_surgery|surgery]]

===References===
# Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E; Spanish Cooperative Group for Digestive Tumor Therapy. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1430-6. Epub 2009 Jun 18. [http://www.redjournal.org/article/S0360-3016(09)00362-9/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19540072 PubMed]
# Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2011 Oct 11. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.26591/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990000 PubMed]

==CLF {{#subobject:74dca8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CLF: '''<u>C</u>'''isplatin, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>F</u>'''luorouracil
<br>PLF: '''<u>P</u>'''latinol (Cisplatin), '''<u>L</u>'''eucovorin (Folinic acid), '''<u>F</u>'''luorouracil
===Variant #1, 12 weeks {{#subobject:e3d573|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0506 Stahl et al. 2009 (POET)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#POET|See link]]
|[[Complex_multipart_regimens#POET|See link]]
|-
|}
''Patients: 100% adenocarcinoma histology. 55% Siewert classification Type I, 45% Siewert classification Types II &III.''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 15, 29
*[[Folinic acid (Leucovorin)]] 500 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36
*[[Fluorouracil (5-FU)]] 2000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 12,000 mg/m<sup>2</sup> )

'''42-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#Cisplatin.2C_Etoposide.2C_RT|Cisplatin, Etoposide, RT]], then [[Surgery#Esophageal_cancer_surgery|surgery]]

===Variant #2, 15 weeks {{#subobject:cf9923|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0506 Stahl et al. 2009 (POET)]
| style="background-color:#1a9851" |Phase III (C)
|PLF x 12 wk, then [[#Cisplatin.2C_Etoposide.2C_RT|Cisplatin, Etoposide, RT]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|}
''Note: this regimen is given for 2.5 cycles, which is a highly unusual instruction; total duration of treatment is 15 weeks.''

''Patients: 100% adenocarcinoma histology. 55% Siewert classification Type I,  45% Siewert classification Types II &III.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 15, 29
*[[Folinic acid (Leucovorin)]] 500 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36 
*[[Fluorouracil (5-FU)]] 2000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 12,000 mg/m<sup>2</sup> )

'''42-day cycle for 2.5 cycles'''
====Subsequent treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]], in 3 to 4 weeks

===References===
# '''POET:''' Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009 Feb 20;27(6):851-6. Epub 2009 Jan 12. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0506 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19139439 PubMed]
## '''Update:''' Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, Wilke H, Budach W. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer. 2017 Aug;81:183-190. [https://www.ncbi.nlm.nih.gov/pubmed/28628843 PubMed]

==CX {{#subobject:ce2bbb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CX: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
<br>XP: '''<u>X</u>'''eloda (Capecitabine), '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:1dd767|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jjco.oxfordjournals.org/content/37/11/829.long Lee et al. 2007]
| style="background-color:#ffffbe" |Retrospective
|-
|}
''The study was for patients with stage IV disease.''

''Patients 97% adenocarcinoma, 3% squamous cell histology; 3% with ECOG PS of 2.''
*Patients with M1b disease (visceral metastases) received the chemotherapy only part until progression of disease or unacceptable toxicity.
*Patients with M1a or M1b (non-viscertal metastases) received 2 cycles of the chemotherapy only part, underwent treatment with chemoradiation, and then treatment continued with--presumably, but not outright specified in the paper--chemotherapy only until progression of disease or unacceptable toxicity.
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''

'''21-day cycles'''
====Subsequent treatment====
*Patients with M1a or M1b disease: [[#Capecitabine.2C_Cisplatin.2C_RT|Definitive capecitabine, cisplatin, RT]]

===References===
# '''Retrospective:''' Lee SS, Kim SB, Park SI, Kim YH, Ryu JS, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn J Clin Oncol. 2007 Nov;37(11):829-35. Epub 2007 Oct 19. [http://jjco.oxfordjournals.org/content/37/11/829.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17951334 PubMed]

==ECF {{#subobject:87a09a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:d40982|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055531 Cunningham et al. 2006 (MAGIC)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#MAGIC|See link]]
|[[Complex_multipart_regimens#MAGIC|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 Al-Batran et al. 2017 (FLOT4-AIO)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|-
|}
''This is the neoadjuvant portion of pre-planned perioperative chemotherapy.''

''Cunningham et al. Patients: 100% adenocarcinoma histology. 75% gastric adenocarcinoma, 15% lower esophagus, 11% gastroesophageal junction.''

''Al-Batran et. al Patients: 100% adenocarcinoma histology of the gastroesophageal  junction (AEG I-III) or the stomach.'' 

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup> )

====Supportive medications====
*MAGIC: [[Warfarin (Coumadin)]] 1 mg PO once per day recommended for thrombosis prophylaxis

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]] occurs 3 to 6 weeks after completing cycle 3, then [[#ECF_2|adjuvant ECF]] is started 6 to 12 weeks after surgery

===References===
# '''MAGIC:''' Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa055531 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16822992 PubMed]
# '''Abstract:''' Salah-Eddin Al-Batran, Nils Homann, Harald Schmalenberg, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Wolff H. Schmiegel, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Peter C. Thuss-Patience, Wolfgang Fischbach, Jorg Trojan, Michael Koenigsmann, Claudia Pauligk, Thorsten Oliver Goetze, Elke Jaeger, Johannes Meiler, Martin H. Schuler, and Ralf Hofheinz. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 link to abstract]

==ECX {{#subobject:c8ab0e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECX: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
===Regimen {{#subobject:27f848|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30043-8/fulltext Cunningham et al. 2017 (UK MRC ST03)]
| style="background-color:#1a9851" |Phase III (C)
|ECX & Bevacizumab
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 Al-Batran et al. 2017 (FLOT4-AIO)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|-
|}
''This is the neoadjuvant portion of pre-planned perioperative chemotherapy.''

''Cunningham et al. Patients: 100% adenocarcinoma histology (36% gastric, 14% lower esophageal, 50% gastroesophageal junction).''

''Al-Batran et al.'' ''Patients: 100% adenocarcinoma histology including gastroesophageal junction (AEG I-III) or the stomach.''

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]], then [[#ECX_2|adjuvant ECX]]

===References===
# Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol. 2017 Mar;18(3):357-370. Epub 2017 Feb 3. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30043-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337626/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28163000 PubMed]
# '''Abstract:''' Salah-Eddin Al-Batran, Nils Homann, Harald Schmalenberg, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Wolff H. Schmiegel, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Peter C. Thuss-Patience, Wolfgang Fischbach, Jorg Trojan, Michael Koenigsmann, Claudia Pauligk, Thorsten Oliver Goetze, Elke Jaeger, Johannes Meiler, Martin H. Schuler, and Ralf Hofheinz. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 link to abstract]

==EOF {{#subobject:ae4e32|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EOF: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:e532ea|Variant=1}}===
''Note: This regimen is sometimes listed as a perioperative option, but it is not clearly described as one by the primary reference to the REAL-2 study. Study participants could have had either locally advanced or metastatic disease, and the primary reference did not list a uniform policy about what patients underwent surgery and its timing--although a few patients were mentioned to undergo surgery.''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>)

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg IV prior to day 1 chemotherapy and 4 mg PO three times per day x 2 days thereafter
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] prior to chemotherapy
*[[Metoclopramide (Reglan)]] 10 mg PO three times per day for 3 days after day 1 chemotherapy
*[[Warfarin (Coumadin)]] 1 mg PO once per day as thrombosis prophylaxis, started on day -1

'''21-day cycle for up to 8 cycles; for perioperative use per some guidelines, 3 cycles preoperatively and 3 cycles postoperatively would be used'''

==EOX {{#subobject:891a3e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EOX: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>X</u>'''eloda (Capecitabine)
<br>EOC: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>C</u>'''apecitabine
===Regimen {{#subobject:6941e|Variant=1}}===
''Note: This regimen is sometimes listed as a perioperative option, but it is not clearly described as one by the primary reference to the REAL-2 study. Study participants could have had either locally advanced or metastatic disease, and the primary reference did not list a uniform policy about what patients underwent surgery and its timing--although a few patients were mentioned to undergo surgery.''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Capecitabine (Xeloda)]] 500 to 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg IV prior to day 1 chemotherapy and 4 mg PO three times per day x 2 days thereafter
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] prior to chemotherapy
*[[Metoclopramide (Reglan)]] 10 mg PO three times per day for 3 days after day 1 chemotherapy

'''21-day cycle for up to 8 cycles; for perioperative use per some guidelines, 3 cycles preoperatively and 3 cycles postoperatively would be used'''

==FLEP {{#subobject:78eabc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FLEP: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:721ee9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2005.00.034 Stahl et al. 2005]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''For historic reference.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]]
*[[Folinic acid (Leucovorin)]]
*[[Etoposide (Vepesid)]]
*[[Cisplatin (Platinol)]]
====Subsequent treatment====
*PE & RT (40 Gy), then [[Surgery#Esophageal_cancer_surgery|surgery]] versus PE & RT (at least 65 Gy)
===References===
# Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005 Apr 1;23(10):2310-7. Erratum in: J Clin Oncol. 2006 Jan 20;24(3):531. [http://ascopubs.org/doi/10.1200/JCO.2005.00.034 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15800321 PubMed]

==FLOT {{#subobject:aa7f4f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FLOT: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>O</u>'''xaliplatin, '''<u>T</u>'''axotere (Docetaxel)
===Regimen {{#subobject:16408e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 Al-Batran et al. 2017 (FLOT4-AIO)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|-
|}
''This is the neoadjuvant portion of pre-planned perioperative chemotherapy.''

''Patients: 100% adenocarcinoma histology of the gastroesophageal junction (AEG I-III) or the stomach'' 
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once on day 1

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]], then [[#FLOT_2|adjuvant FLOT]]
===References===
# '''Abstract:''' Salah-Eddin Al-Batran, Nils Homann, Harald Schmalenberg, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Wolff H. Schmiegel, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Peter C. Thuss-Patience, Wolfgang Fischbach, Jorg Trojan, Michael Koenigsmann, Claudia Pauligk, Thorsten Oliver Goetze, Elke Jaeger, Johannes Meiler, Martin H. Schuler, and Ralf Hofheinz. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 link to abstract]

==PCF {{#subobject:747f5e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCF: '''<u>P</u>'''aclitaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:2d319e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.jto.org/article/S1556-0864(15)33583-8/fulltext Zhao et al. 2015]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 2
*[[Fluorouracil (5-FU)]] 700 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3500 mg/m<sup>2</sup>)

'''2 cycles'''
====Subsequent treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]], then adjuvant PCF x 2 versus no further treatment

===References===
# Zhao Y, Dai Z, Min W, Sui X, Kang H, Zhang Y, Ren H, Wang XJ. Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial. J Thorac Oncol. 2015 Sep;10(9):1349-1356. [https://www.jto.org/article/S1556-0864(15)33583-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26287319 PubMed]

=Neoadjuvant chemoradiotherapy=
''Note: while these regimens are listed as neoadjuvant (pre-operative), in some cases they are also used as definitive therapy in patients that are not surgical candidates.''
==Capecitabine, Carboplatin, Paclitaxel, RT {{#subobject:79bb5a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:f22688|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.redjournal.org/article/S0360-3016(06)03362-1/abstract Czito et al. 2006]
| style="background-color:#ffffbe" |Pilot, <20 pts
|-
|}
''The primary reference did not specify whether patients were intended to proceed to surgery.''

''Patients: 77% adenocarcinoma, 23% squamous cell histology. 54% lower thoracic, 23% midthoracic, 23% gastroesophageal junction.''
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 1.5 IV once per day on days 2, 9, 16, 23, 30
*[[Paclitaxel (Taxol)]] 45 mg/m<sup>2</sup> IV over 60 minutes once per day on days 2, 9, 16, 23, 30 
*[[Capecitabine (Xeloda)]] 600 mg/m<sup>2</sup> PO twice per day, starting on day 1 and finishing the evening of the last day of radiation therapy
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 28 fractions given 5 days per week, for a total dose of 50.4 Gy, starting on day 1

'''6-week course'''

====Subsequent treatment====
*Patients were evaluated for [[Surgery#Esophagectomy|surgery]], performed 6 to 8 weeks after chemoradiotherapy completion. Patients could receive adjuvant chemotherapy, beginning 4 to 12 weeks postoperatively

===References===
# '''Phase I:''' Czito BG, Kelsey CR, Hurwitz HI, Willett CG, Morse MA, Blobe GC, Fernando NH, D'Amico TA, Harpole DH, Honeycutt W, Yu D, Bendell JC. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1002-7. Epub 2006 Dec 29. [http://www.redjournal.org/article/S0360-3016(06)03362-1/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17197129 PubMed]

==Capecitabine, Cisplatin, RT {{#subobject:ae7180|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:eccd56|Variant=1}}===
''Note: This study was for patients with stage IV disease. Please reference the original paper, as there were no patients who only received this neoadjuvant treatment, and they did not undergo surgical resection of disease.''

''Patients: 3% adenocarcinoma, 97% squamous cell histology; 3% with ECOG PS of 2.''
====Preceding treatment====
*Capecitabine & Cisplatin

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV over 60 minutes once on day 1 and repeated weekly while radiation is being given, '''given before the first dose of capecitabine'''
*[[Capecitabine (Xeloda)]] 800 mg/m<sup>2</sup> PO twice per day, 5 days per week while radiation is being given
*Concurrent [[External_beam_radiotherapy|radiation therapy]], total of 54 Gy given (dose per fraction and total duration of treatment was not specified)

'''1-week cycles until radiation therapy is complete'''

===References===
# Lee SS, Kim SB, Park SI, Kim YH, Ryu JS, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn J Clin Oncol. 2007 Nov;37(11):829-35. Epub 2007 Oct 19. [http://jjco.oxfordjournals.org/content/37/11/829.long link to original article] '''contains verified protocol'''--please see note above, as patients in this study did not undergo surgery [https://www.ncbi.nlm.nih.gov/pubmed/17951334 PubMed]

==Capecitabine, Docetaxel, RT {{#subobject:ff7031|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:d49e8|Variant=1}}===
''Note: No primary reference could be found for this regimen; the reference below is for reference purposes only.''
====Chemoradiotherapy====
*[[Docetaxel (Taxotere)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29
*[[Capecitabine (Xeloda)]] 625 to 825 mg/m<sup>2</sup> PO twice per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33
*Concurrent [[External_beam_radiotherapy|radiation therapy]] not defined

'''5-week course'''

===References===
# '''Phase I:''' Wood MD, Zaki BI, Gordon SR, Sutton JE Jr, Lisovsky M, Gui J, Bubis JA, Dragnev KH, Rigas JR. Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy. J Thorac Oncol. 2013 Apr;8(4):487-94. [https://www.jto.org/article/S1556-0864(15)32794-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600150/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23370365 PubMed]

==Capecitabine, Docetaxel, Oxaliplatin, RT {{#subobject:312400|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:e65189|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/13/2213.long Spigel et al. 2010]
| style="background-color:#91cf61" |Phase I/II
|-
|}
''Patients: 69% adenocarcinoma, 18% squamous cell, 12% not otherwise specified. 69% distal esophagus, 16% midesophagus, 14% gastroesophageal junction.''

====Chemoradiotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 7, 15 to 21, 29 to 35 
*[[Docetaxel (Taxotere)]] 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, 22, 29
*[[Oxaliplatin (Eloxatin)]] 40 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions, for a total dose of 45 Gy. Patients who were no longer surgical candidates received additional radiation therapy to a total dose of 64.8 Gy.

====Supportive medications====
*[[Dexamethasone (Decadron)]] 4 mg PO every 12 hours before, at the time of, and after [[Docetaxel (Taxotere)]]; first dose the evening before [[Docetaxel (Taxotere)]]
*"Routine antiemetics"

'''5-week course of therapy'''
====Subsequent treatment====
*Endoscopy, CT scan, and--if available--endoscopic ultrasound for restaging 2 to 4 weeks after finishing chemoradiation. [[Surgery#Esophagectomy|Surgical resection]] for appropriate candidates during weeks 9 to 12

===References===
# Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2010 May 1;28(13):2213-9. Epub 2010 Mar 29. [http://jco.ascopubs.org/content/28/13/2213.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20351330 PubMed]

==Capecitabine, Oxaliplatin, RT {{#subobject:e958eb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:69d2ce|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.1080/07357900802172093 Javle et al. 2009]
| style="background-color:#ffffbe" |Phase I
|-
|}
====Chemoradiotherapy====
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33 
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once per day on days 1, 15, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]], total dose of 50.4 Gy

'''5-week course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]]
===References===
# '''Phase I:''' Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, Schiff MD, Nava HR, LeVea C, Clark KR, Prey JD, Smith PF, Pendyala L. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest. 2009 Feb;27(2):193-200. [https://www.tandfonline.com/doi/full/10.1080/07357900802172093 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19235592 PubMed]

==Capecitabine, Paclitaxel, RT {{#subobject:17bbec|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:c6f9f5|Variant=1}}===
====Chemoradiotherapy====
*[[Capecitabine (Xeloda)]] 625 to 825 mg/m<sup>2</sup> PO twice per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33 
*[[Paclitaxel (Taxol)]] 45 to 50 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]] not defined

'''5-week course'''
===References===
# No primary reference could be found for this regimen.

==Carboplatin, Fluorouracil, RT {{#subobject:d29415|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:1c21a7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1442-2050.2009.00984.x/full Zemanoa et al. 2009]
| style="background-color:#91cf61" |Non-randomized
|-
|}
''Patients: 86% squamous cell, 8% adenocarcinoma, 6% other histology. 3% ECOG PS of 2.''

====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once per day on days 1 & 22
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose per cycle: 8400 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week, starting on day 1, for a total dose of 45 Gy. If surgery was contraindicated, total dose was increased to 50.4 to 56.8 Gy.
*Upper endoscopy and CT chest and abdomen was performed after completion of chemoradiation

'''42-day course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]] planned to be done 4 to 6 weeks after finishing chemoradiation

===References===
# Zemanova M, Petruzelka L, Pazdro A, Kralova D, Smejkal M, Pazdrova G, Honova H. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Dis Esophagus. 2010 Feb;23(2):160-7. Epub 2009 Jun 9. [https://onlinelibrary.wiley.com/doi/10.1111/j.1442-2050.2009.00984.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19515190 PubMed]

==Carboplatin, Paclitaxel, RT {{#subobject:93878b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:33b67a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361286 van Meerten et al. 2006]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1112088 van Hagen et al. 2012 (CROSS)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#1a9850" |Superior OS
|-
|}
''van Meerten et al. Patients: 76% adenocarcinoma, 22% squamous cell, 2% large cell histology. 91% lower esophagus, 9% thoracic esophagus''

''van Hagen et al. Patients: 75% adenocarcinoma, 23% squamous cell, 2% other. 24% gastroesophageal junction''

====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV once per day on days 1, 8, 15, 22, 29, '''given second'''
*[[Paclitaxel (Taxol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22, 29, '''given first'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 23 fractions given 5 days per week, starting on day 1, for a total dose of 41.4 Gy

====Supportive medications====
*[[Dexamethasone (Decadron)]] 10 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Ranitidine (Zantac)]] 50 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Clemastine (Tavist)]] 2 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*Between paclitaxel & carboplatin: 100 mL NS given over 30 minutes, then [[Ondansetron (Zofran)]] 8 mg in 100 mL NS given over 30 minutes

'''5-week course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]] planned to be done within 6 weeks of finishing chemoradiation; van Hagen et al. 2012 said surgery was done as soon as possible after finishing chemoradiotherapy, preferably within 4 to 6 weeks

===References===
# van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer. 2006 May 22;94(10):1389-94. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361286 link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361286/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16670722 PubMed]
# '''CROSS:''' van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. [https://www.nejm.org/doi/full/10.1056/NEJMoa1112088 link to original article] '''contains verified protocol''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1112088/suppl_file/nejmoa1112088_appendix.pdf link to appendix with details about administration] [https://www.ncbi.nlm.nih.gov/pubmed/22646630 PubMed]
## '''Update:''' Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1090-1098. Epub 2015 Aug 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00040-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26254683 PubMed]

==Cisplatin, Docetaxel, RT {{#subobject:4231cb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:6c3cc6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/20/9/1522.long Ruhstaller et al. 2009 (SAKK 75/02)]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 55% adenocarcinoma, 45% squamous cell histology''

====Preceding treatment====
*[[#Cisplatin_.26_Docetaxel|Cisplatin & Docetaxel]] x 2

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29
*[[Docetaxel (Taxotere)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week, starting on day 1, for a total dose of 45 Gy

'''5-week course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]], 3 to 8 weeks after finishing chemoradiation

===References===
# Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, Köberle D, Terraciano L, Schnider A, Bodis S, Popescu R; Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol. 2009 Sep;20(9):1522-8. Epub 2009 May 22. [http://annonc.oxfordjournals.org/content/20/9/1522.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19465425 PubMed]

==Cisplatin, Etoposide, RT {{#subobject:88cc36|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:a9fc90|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0506 Stahl et al. 2009 (POET)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#POET|See link]]
|[[Complex_multipart_regimens#POET|See link]]
|-
|}
''Patients: 100% adenocarcinoma histology. 55% Siewert classification Type I, 45% Siewert classification Types II &III.''

====Preceding treatment====
*[[#CLF|PLF]] x 12 wk

====Chemoradiotherapy, ''to start 2 weeks after the last day of PLF''====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8
*[[Etoposide (Vepesid)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 3 to 5
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.0 Gy fractions x 15 fractions, five days per week, for a target dose of 30 Gy
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]], in 3 to 4 weeks

===References===
# '''POET:''' Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009 Feb 20;27(6):851-6. Epub 2009 Jan 12. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0506 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19139439 PubMed]
## '''Update:''' Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, Wilke H, Budach W. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer. 2017 Aug;81:183-190. [https://www.ncbi.nlm.nih.gov/pubmed/28628843 PubMed]

==Cisplatin, Fluorouracil, RT {{#subobject:17919|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF & RT: '''</u>C</u>'''isplatin, '''<u>F</u>'''luourouracil, '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 75/3200 x 2 {{#subobject:e20717|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2013.53.6532 Mariette et al. 2014 (FFCD 9901)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1 or 2
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3200 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.80 Gy fractions x 25 fractions, 5 days per week, for a total dose of 45 Gy

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]]

===Variant #2, 75/4000 x 2 {{#subobject:a49842|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/25/10/1160.long Bedenne et al. 2007 (FFCD 9102)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Patients: 89% epidermoid, 11% glandular histology.''

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 15 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 5
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 23 fractions given 5 days per week, for a total dose of 46 Gy
**Earlier in the study, some patients instead received split-course radiation therapy, 3 Gy fractions x 5 fractions given on days 1 to 5. 15 Gy per cycle; total dose after 2 cycles is 30 Gy.

====Supportive medications====
*1 liter NS IV over 2 hours before and after [[Cisplatin (Platinol)]]

'''21-day cycle for 2 cycles'''   
====Subsequent treatment====
*[[#Cisplatin.2C_Fluorouracil.2C_RT_2|Cisplatin, Fluorouracil, RT (no surgery)]] x 3 (5 cycles total) versus [[Surgery#Esophagectomy|surgery]], 50 to 60 days after start of chemoradiation

===Variant #3, 80/3200 {{#subobject:b4cc81|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70288-6/fulltext Burmeister et al. 2005]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3200 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.33 Gy fractions x 15 fractions for a total dose of 35 Gy

'''One course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]]

===Variant #4, 100/4000 x 2 {{#subobject:45f8a2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126644/ Tepper et al. 2008 (CALGB 9781)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#1a9850" |Superior OS
|-
|}
''Patients: 75% adenocarcinoma, 25% squamous cell histology. 5% with ECOG PS of 2.'' 

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 30 minutes once on day 1, '''given first'''
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1, '''given second''' (total dose per cycle: 4000 mg/m<sup>2</sup>) 
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week, then a 5.4 Gy final boost, for a total dose of 50.4 Gy, '''starting within 24 hours of start of chemotherapy'''

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*EGD and CT chest and abdomen done within 4 weeks after finishing radiation therapy. Only patients who still had resectable disease that was stable or responded would proceed to [[Surgery#Esophagectomy|surgery]]. Surgery was planned to be done 3 to 8 weeks after finishing chemoradiation.

===Variant #5, intermittent 5-FU {{#subobject:213574|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199608153350702 Walsh et al. 1996]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#1a9850" |Superior OS
|-
|}
''Note: of historic interest only.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]]
*[[Fluorouracil (5-FU)]]
*Concurrent [[External_beam_radiotherapy|radiation therapy]]
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]]
===References===
# Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996 Aug 15;335(7):462-7. Erratum in: N Engl J Med 1999 Jul 29;341(5):384. [https://www.nejm.org/doi/full/10.1056/NEJM199608153350702 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8672151 PubMed]
# Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005 Sep;6(9):659-68. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70288-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16129366 PubMed]
# '''FFCD 9102:''' Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007 Apr 1;25(10):1160-8. [http://jco.ascopubs.org/content/25/10/1160.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17401004 PubMed]
# '''CALGB 9781:''' Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086-92. [http://jco.ascopubs.org/content/26/7/1086.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126644/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18309943 PubMed]
# '''FFCD 9901:''' Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, Bosset JF, Mabrut JY, Triboulet JP, Bedenne L, Seitz JF. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014 Aug 10;32(23):2416-22. Epub 2014 Jun 30. [http://ascopubs.org/doi/full/10.1200/JCO.2013.53.6532 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24982463 PubMed]

==Cisplatin, Irinotecan, RT {{#subobject:4932b1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1 {{#subobject:eac274|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563156/ Yoon et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% adenocarcinoma of the esophagus or gastroesophageal junction (tumor extension < 2cm into gastric cardia)''

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1, 8, 22, 29
*[[Irinotecan (Camptosar)]] 65 mg/m<sup>2</sup> IV once per day on days 1, 8, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week, starting within 24 hours of the first dose of chemotherapy, for a total dose of 45 Gy.

'''5-week course'''
====Subsequent treatment====
*Yoon et al. 2011: [[Surgery#Esophagectomy|surgery]] at least 28 days after finishing chemoradiation, then begin [[#Cisplatin_.26_Irinotecan_2|adjuvant cisplatin & irinotecan]] at least 28 days after surgical resection

===Variant #2 {{#subobject:927613|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.26591/full Ilson et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 75% adenocarcinoma, 22% squamous cell, 3% poorly differentiated history; 33% gastroesophageal junction.''

====Preceding treatment====
*[[#Cisplatin_.26_Irinotecan|Cisplatin & Irinotecan induction]] x 2
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8, '''given first'''
*[[Irinotecan (Camptosar)]] 65 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8, '''given second'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 28 fractions given 5 days per week, for a total of 50.4 Gy given

'''21-day cycle for 2 cycles''' 
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]], performed 4 to 8 weeks after chemoradiation

===Variant #3 {{#subobject:1a3475|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.redjournal.org/article/S0360-3016(09)00362-9/abstract Rivera et al. 2009]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% adenocarcinoma histology (43% gastroesophageal junction, 57% gastric adenocarcinoma)''

====Preceding treatment====
*[[#Cisplatin_.26_Irinotecan|Cisplatin & Irinotecan induction]] x 2
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
*[[Irinotecan (Camptosar)]] 65 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week, starting within 24 hours of the first dose of chemotherapy, for a total dose of 45 Gy.

'''5-week course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]], 5 to 8 weeks after finishing chemoradiation

===References===
# Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E; Spanish Cooperative Group for Digestive Tumor Therapy. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1430-6. Epub 2009 Jun 18. [http://www.redjournal.org/article/S0360-3016(09)00362-9/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19540072 PubMed]
# Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2011 Oct 11. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.26591/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990000 PubMed]
# Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011 Oct;68(4):863-70. Epub 2011 Feb 1. [http://www.springerlink.com/content/v4g0257025185531/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563156/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21286719 PubMed]

==Cisplatin, Paclitaxel, RT {{#subobject:3d8eaa|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, weekly cisplatin {{#subobject:5a433d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563156/ Yoon et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% adenocarcinoma of the esophagus or gastroesophageal junction (tumor extension < 2cm into gastric cardia)''

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29
*[[Paclitaxel (Taxol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week, starting within 24 hours of the first dose of chemotherapy, for a total dose of 45 Gy.

'''5-week course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]] at least 28 days after finishing chemoradiation, then [[#Cisplatin_.26_Paclitaxel|adjuvant cisplatin & paclitaxel]] at least 28 days after surgical resection

===Variant #2, q3wk cisplatin {{#subobject:32166d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.11759/full Urba et al. 2003]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 83% adenocarcinoma, 14% squamous cell, 3% undifferentiated histology''

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Paclitaxel (Taxol)]] 60 mg/m<sup>2</sup> IV over 3 hours once per day on days 1, 8, 15, 22
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.5 Gy fractions given twice per day on days 1 to 5, 8 to 12, 15 to 19, with at least 6 hours between fractions, for a total dose of 45 Gy

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg PO given 12 and 6 hours before [[Paclitaxel (Taxol)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Cimetidine (Tagamet)]] 300 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*1 liter D5NS and mannitol 12.5 g bolus IV prior to [[Cisplatin (Platinol)]]
*Mannitol 25 g in 1 liter D5NS IV over 4 hours after [[Cisplatin (Platinol)]]
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting 24 hours after the fourth dose of [[Paclitaxel (Taxol)]], continuing until ANC greater than 10,000/uL

'''4-week course'''
====Subsequent treatment====
*Barium swallow and CT chest and abdomen done about 1 week prior to surgery to rule out metastatic disease. [[Surgery#Esophagectomy|Surgery]] to be done on approximately day 50

===References===
# Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer. 2003 Nov 15;98(10):2177-83. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.11759/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14601087 PubMed]
# Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011 Oct;68(4):863-70. Epub 2011 Feb 1. [http://www.springerlink.com/content/v4g0257025185531/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563156/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21286719 PubMed]

==Cisplatin, Vinorelbine, RT {{#subobject:d72171|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, standard cisplatin {{#subobject:ddf0ee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145832/ Yang et al. 2018 (NEOCRTEC5010)]
| style="background-color:#1a9851" |Phase III (E)
|[[#No_neoadjuvant_therapy|No neoadjuvant therapy]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once per day on days 1 & 22
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.0 Gy fractions x 20 fractions given 5 days per week, starting on the first day of chemotherapy, for a total dose of 40 Gy

'''4-week course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]]

===Variant #2, split-dose cisplatin {{#subobject:672470|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145832/ Yang et al. 2018 (NEOCRTEC5010)]
| style="background-color:#1a9851" |Phase III (E)
|[[#No_neoadjuvant_therapy|No neoadjuvant therapy]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV once per day on days 1 to 4, 22 to 25
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.0 Gy fractions x 20 fractions given 5 days per week, starting on the first day of chemotherapy, for a total dose of 40 Gy

'''4-week course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]]
===References===
# '''NEOCRTEC5010:''' Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018 Sep 20;36(27):2796-2803. Epub 2018 Aug 8. [http://ascopubs.org/doi/full/10.1200/JCO.2018.79.1483 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145832/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/30089078 PubMed]

==Docetaxel, Fluorouracil, RT {{#subobject:956374|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1 {{#subobject:c112ab|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ar.iiarjournals.org/content/27/4C/2597.long Hihara et al. 2007]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 86% squamous cell, 14% carcinosarcoma histology''

====Chemoradiotherapy====
*[[Docetaxel (Taxotere)]] 7.5 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 250 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on days 1, 8, 15 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 30 to 33 fractions given 5 days per week, for a total dose of 60 to 66 Gy, starting on cycle 1 day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg IV once 30 minutes prior to [[Docetaxel (Taxotere)]]

'''28-day cycle for 2 cycles'''

===Variant #2 {{#subobject:8dd58b|Variant=1}}===
''Note: No primary reference could be found for this regimen.''
====Chemoradiotherapy====
*[[Docetaxel (Taxotere)]] 20 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 200 to 300 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1
*Concurrent [[External_beam_radiotherapy|radiation therapy]] not defined

'''7-day cycle for 5 cycles'''

===References===
# '''Phase I:''' Hihara J, Yoshida K, Hamai Y, Emi M, Yamaguchi Y, Wadasaki K. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2597-603. [http://ar.iiarjournals.org/content/27/4C/2597.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17695421 PubMed]

==Fluorouracil, Oxaliplatin, RT {{#subobject:94b79a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 45 Gy {{#subobject:bbd435|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567089 Lorenzen et al. 2008]
| style="background-color:#91cf61" |Phase I/II
|-
|}
''Patients: 100% squamous cell etiology, 65% poor differentiated or undifferentiated''

====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]] 225 mg/m<sup>2</sup>/day IV continuous infusion over 33 days, started on day 1 (total dose: 7425 mg/m<sup>2</sup>) 
*[[Oxaliplatin (Eloxatin)]] 45 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week, for a total dose of 45 Gy

'''35-day course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]], 4 to 6 weeks after finishing chemoradiation

===Variant #2, 50.4 Gy, bi-weekly oxaliplatin {{#subobject:ae22de|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/20/12/2844.long Khushalani et al. 2002]
| style="background-color:#91cf61" |Phase II
|-
|}
''58% patients were classified as stage IV disease''

====Chemoradiotherapy====
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29
*[[Fluorouracil (5-FU)]] 180 mg/m<sup>2</sup>/day IV continuous infusion over 35 days, started on day 8 (total dose: 6300 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 20 to 22 fractions, for an initial total dose of 36 to 39.6 Gy, '''started on day 8'''
**Followed by off-cord conformal oblique fields, 5.4 to 9 Gy given to the clinical target volume (CTV). A second off-cord phase to the gross tumor volume (GTV) of 5.4 Gy was then given, for a total dose delivered of 50.4 Gy to the GTV.

'''42-day course'''

====Subsequent treatment====
*Upper GI endoscopy and CT chest, abdomen, and pelvis were done after completion of chemoradiation, and patients without progressive stage II-III disease were offered [[Surgery#Esophagectomy|surgery]] followed by another cycle of oxaliplatin and 5-FU. Patients who could not proceed to surgery were given another 1 to 2 cycles of oxaliplatin and 5-FU within 2 weeks.

===Variant #3, 50.4 Gy, weekly oxaliplatin {{#subobject:aa7e55|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937600/ Ajani et al. 2013]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: it is unclear how long the 5-FU continuous infusions were in this regimen; the authors have been contacted for clarification.''
====Preceding treatment====
*Fluorouracil & Oxaliplatin induction versus no induction chemotherapy
====Chemoradiotherapy====
*[[Oxaliplatin (Eloxatin)]] 40 mg/m<sup>2</sup> IV once per week
*[[Fluorouracil (5-FU)]] 250 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on Mondays (total dose: 5000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 50.4 Gy of proton or photon (intensity modulated) radiation in 28 fractions

'''One 5-week course'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]]
===References===
# Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002 Jun 15;20(12):2844-50. [http://jco.ascopubs.org/content/20/12/2844.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12065561 PubMed]
# Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K, Peschel C, Siewert JR, Molls M, Lordick F. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer. 2008 Oct 7;99(7):1020-6. Epub 2008 Sep 16. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567089 link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567089/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18797462 PubMed]
# Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov;24(11):2844-9. Epub 2013 Aug 23. [https://academic.oup.com/annonc/article/24/11/2844/201894 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937600/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23975663 PubMed]

==Fluorouracil, Paclitaxel, RT {{#subobject:52e768|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:f8576f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/24/3953.long Ajani et al. 2006 (RTOG 9904)]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% adenocarcinoma histology. The majority of patients had gastric adenocarcinoma. Although gastroesophageal junction was involved, percentages were not included.''

====Preceding treatment====
*[[#Cisplatin_.26_Fluorouracil|Cisplatin & 5-FU induction]] x 2
====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 1500 mg/m<sup>2</sup>) 
*[[Paclitaxel (Taxol)]] 45 mg/m<sup>2</sup> IV once on day 1
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week, for a total dose of 45 Gy

'''7-day cycle for 5 cycles'''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]]
===References===
# '''RTOG 9904:''' Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006 Aug 20;24(24):3953-8. [http://jco.ascopubs.org/content/24/24/3953.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16921048 PubMed]

==No neoadjuvant therapy==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199608153350702 Walsh et al. 1996]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199707173370304 Bosset et al. 1997]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin & RT
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199812313392704 Kelsen et al. 1998 (RTOG 8911)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Fluorouracil|CF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.2.305 Urba et al. 2001]
| style="background-color:#1a9851" |Randomized Phase II (C)
|Cisplatin, 5-FU, Vinblastine, RT
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142%2820010601%2991%3A11%3C2165%3A%3AAID-CNCR1245%3E3.0.CO%3B2-H Ancona et al. 2001]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Fluorouracil|CF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08651-8/fulltext Girling et al. 2002 (UK MRC OE02)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Fluorouracil|CF]]
| style="background-color:#fc8d59" |Seems to have inferior OS (*)
|-
|[https://academic.oup.com/annonc/article/15/6/947/129993 Lee et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70288-6/fulltext Burmeister et al. 2005]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055531 Cunningham et al. 2006 (MAGIC)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#MAGIC|Perioperative ECF]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126644/ Tepper et al. 2008 (CALGB 9781)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
| style="background-color:#d73027" |Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.0597 Ychou et al. 2011 (ACCORD 07)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#ACCORD_07|Perioperative CF]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123658/ Boonstra et al. 2011]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Etoposide|EP]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1112088 van Hagen et al. 2012 (CROSS)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Carboplatin.2C_Paclitaxel.2C_RT|Carboplatin, Paclitaxel, RT]]
| style="background-color:#d73027" |Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2013.53.6532 Mariette et al. 2014 (FFCD 9901)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145832/ Yang et al. 2018 (NEOCRTEC5010)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin.2C_Vinorelbine.2C_RT|Cisplatin, Vinorelbine, RT]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''Note: efficacy for UK MRC OE02 is based on the 2009 update.''

''Surgery as primary therapy; i.e., no induction chemotherapy or chemoradiotherapy, and no adjuvant therapy.''

''MAGIC patients: 100% adenocarcinoma of the stomach or lower third of the esophagus. 74% gastric, 15% lower esophagus, 11% gastroesophageal  junction.''

''CALGB 9781 patients: 75% adenocarcinoma, 25% squamous cell histology. 5% with ECOG PS of 2.''

''CROSS patients: 75% adenocarcinoma, 23% squamous cell, 2% other. 24% gastroesophageal  junction.''
====Subsequent treatment====
*[[Surgery#Esophagectomy|Surgery]]

===References===
# Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996 Aug 15;335(7):462-7. Erratum in: N Engl J Med 1999 Jul 29;341(5):384. [https://www.nejm.org/doi/full/10.1056/NEJM199608153350702 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8672151 PubMed]
# Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997 Jul 17;337(3):161-7. [https://www.nejm.org/doi/full/10.1056/NEJM199707173370304 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9219702 PubMed]
# '''RTOG 8911:''' Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31;339(27):1979-84. [https://www.nejm.org/doi/full/10.1056/NEJM199812313392704 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9869669 PubMed]
## '''Update:''' Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG; Radiation Therapy Oncology Group; USA Intergroup. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007 Aug 20;25(24):3719-25. [http://ascopubs.org/doi/full/10.1200/JCO.2006.10.4760 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17704421 PubMed]
# Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001 Jan 15;19(2):305-13. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.2.305 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11208820 PubMed]
# Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001 Jun 1;91(11):2165-74. [https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142%2820010601%2991%3A11%3C2165%3A%3AAID-CNCR1245%3E3.0.CO%3B2-H link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11391598 PubMed]
# '''UK MRC OE02:''' Girling DJ, Bancewicz J, Clark PI, Smith DB, Donnelly RJ, Fayers PM, Weeden S, Hutchinson T, Harvey A, Lyddiard J; Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1727-33. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08651-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12049861 PubMed]
## '''Update:''' Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009 Oct 20;27(30):5062-7. Epub 2009 Sep 21. [http://ascopubs.org/doi/full/10.1200/JCO.2009.22.2083 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19770374 PubMed]
# Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH, Min YI. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 2004 Jun;15(6):947-54. [https://academic.oup.com/annonc/article/15/6/947/129993 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15151953 PubMed]
# Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005 Sep;6(9):659-68. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70288-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16129366 PubMed]
# '''MAGIC:''' Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa055531 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16822992 PubMed]
# '''CALGB 9781:''' Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086-92. [http://jco.ascopubs.org/content/26/7/1086.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126644/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18309943 PubMed]
# '''ACCORD 07:''' Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. Epub 2011 Mar 28. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.0597 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21444866 PubMed]
# Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, Siersema PD, Dinjens WN, van Lanschot JJ, Tilanus HW, van der Gaast A. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011 May 19;11:181. [https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-181 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123658/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21595951 PubMed]
# '''CROSS:''' van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. [https://www.nejm.org/doi/full/10.1056/NEJMoa1112088 link to original article] '''contains verified protocol''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1112088/suppl_file/nejmoa1112088_appendix.pdf link to appendix with details about administration] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22646630 PubMed]
## '''Update:''' Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1090-1098. Epub 2015 Aug 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00040-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26254683 PubMed]
# '''FFCD 9901:''' Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, Bosset JF, Mabrut JY, Triboulet JP, Bedenne L, Seitz JF. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014 Aug 10;32(23):2416-22. Epub 2014 Jun 30. [http://ascopubs.org/doi/full/10.1200/JCO.2013.53.6532 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24982463 PubMed]
# '''NEOCRTEC5010:''' Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018 Sep 20;36(27):2796-2803. Epub 2018 Aug 8. [http://ascopubs.org/doi/full/10.1200/JCO.2018.79.1483 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145832/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/30089078 PubMed]

=Definitive therapy=

==Capecitabine, Cisplatin, RT {{#subobject:dfe688|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1 {{#subobject:4beb7f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70136-0/abstract Crosby et al. 2013 (SCOPE1)]
| style="background-color:#1a9851" |Phase III (C)
|Capecitabine, Cisplatin, Cetuximab, RT
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|}
''Note: efficacy is based on the 2017 update.''

''Patients: 25% adenocarcinoma, 73% squamous cell, 2% undifferentiated histology''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21
**If patients were unable to swallow capecitabine, they could receive fluorouracil infusion dose 225 mg/m<sup>2</sup> per day on days 1 to 21 of each cycle (total dose: 4725mg/m<sup>2</sup> per cycle)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], total of 50 Gy given in 25 fractions with cycles 3 & 4

'''21-day cycle for 4 cycles'''

===Variant #2 {{#subobject:f7a6c1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jjco.oxfordjournals.org/content/37/11/829.long Lee et al. 2007]
| style="background-color:#ffffbe" |Retrospective
|-
|}
''Patients: 97% adenocarcinoma, 3% squamous cell histology; 3% with ECOG PS of 2.''

''The study was for patients with stage IV disease.''
*Patients with M1b disease (visceral metastases) received the chemotherapy only part until progression of disease or unacceptable toxicity.
*Patients with M1a or M1b (non-viscertal metastases) received 2 cycles of the chemotherapy only part, underwent treatment with chemoradiation, and then treatment continued with--presumably, but not outright specified in the paper--chemotherapy only until progression of disease or unacceptable toxicity.
====Preceding treatment====
*[[#CX|XP]] x 2
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV over 60 minutes once on day 1 and repeated weekly while radiation is being given, '''given first'''
*[[Capecitabine (Xeloda)]] 800 mg/m<sup>2</sup> PO twice per day, 5 days per week while radiation is being given
*Concurrent [[External_beam_radiotherapy|radiation therapy]], total of 54 Gy given. Dose per fraction and total duration of treatment were not specified, but based on other regimens, it is suspected to be either 1.8 Gy x 30 fractions or 2 Gy x 27 fractions.

'''1-week cycles until radiation therapy is complete'''

===References===
# '''Retrospective:''' Lee SS, Kim SB, Park SI, Kim YH, Ryu JS, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn J Clin Oncol. 2007 Nov;37(11):829-35. Epub 2007 Oct 19. [http://jjco.oxfordjournals.org/content/37/11/829.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17951334 PubMed]
# Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013 Jun;14(7):627-37. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70136-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23623280 PubMed]
## '''Update:''' Crosby T, Hurt CN, Falk S, Gollins S, Staffurth J, Ray R, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G, Mukherjee S. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. Br J Cancer. 2017 Mar 14;116(6):709-716. Epub 2017 Feb 14. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355926/ link to original article] '''contains verified protocol'''  [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355926/ link to PMC article] '''contains verified protocol'''  [https://www.ncbi.nlm.nih.gov/pubmed/28196063 PubMed]

==Cisplatin, Docetaxel, RT {{#subobject:21719f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1 {{#subobject:7b3f9c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1442-2050.2009.01003.x/full Li et al. 2009]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% squamous cell histology, 5% gastroesophageal junction. 44% of patients had stage IV disease''

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once per day on days 1 & 22
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once per day on days 1 & 22
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 to 2.0 Gy fractions, 5 days per week, to start within 24 hours of the day 1 of chemotherapy
**Patients with stage I to III disease received a total dose of 60 to 64 Gy over 4 to 6 weeks
**Patients with stage IV disease (lymph node only) received a total dose of 50 to 56 Gy
''Note, dose reductions were permitted, see article for specifications'' 

====Supportive medications====
*[[Dexamethasone (Decadron)]] 10 mg IV or PO the day before [[Docetaxel (Taxotere)]], 30 minutes prior to [[Docetaxel (Taxotere)]], and the day after [[Docetaxel (Taxotere)]]
*[[Diphenhydramine (Benadryl)]] 40 mg IV prior to chemotherapy
*[[Cimetidine (Tagamet)]] 40 mg IV prior to chemotherapy
*[[Granisetron]] 2 mg IV prior to chemotherapy
*1.5 to 2.0 liters fluids before [[Cisplatin (Platinol)]]

'''1 course'''

===Variant #2 {{#subobject:f4800d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031899 Day et al. 2010]
| style="background-color:#ffffbe" |Phase I
|-
|}
''Patients: 46% squamous cell, 54% adenocarcinoma histology'' 

''Note: some guidelines suggest a wider dose range of 20 to 30 mg/m<sup>2</sup> for both cisplatin and docetaxel. The primary reference also investigated these dose levels, but ultimately recommended 30 mg/m<sup>2</sup> dosages for both cisplatin and docetaxel.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29
*[[Docetaxel (Taxotere)]] 30 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 25 fractions, 5 days per week, for a total dose of 50 Gy, to start within 4 hours after the first dose of chemotherapy. 

====Supportive medications====
*"Steroid and anti-emetic pre-medication"

'''5-week course'''

===References===
# Li QQ, Liu MZ, Hu YH, Liu H, He ZY, Lin HX. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus. 2010 Apr;23(3):253-9. Epub 2009 Aug 28. [https://onlinelibrary.wiley.com/doi/10.1111/j.1442-2050.2009.01003.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19732130 PubMed]
# '''Phase I:''' Day FL, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg JR, Rischin D, McKendick J, Milner AD, Di Iulio J, Matera A, Michael M. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2011 Jan 18;104(2):265-71. Epub 2010 Dec 14. [https://www.nature.com/articles/6606051 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031899/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21157450 PubMed]

==Cisplatin, Fluorouracil, RT {{#subobject:2b3dbc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF & RT: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil, '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 50 Gy {{#subobject:ca1b71|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199206113262403 Herskovic et al. 1992 (RTOG 85-01)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
| style="background-color:#1a9850" |Superior OS
|-
|}
''Patients: 88% squamous cell, 12% adenocarcinoma histology. 7% karnofsky performance scale of 50-60.''

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once per day on the first day of week 1, 5, 8, 11 (day 1, 29, 50, 71)
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on the Monday of week 1, 5, 8, 11 (total dose: 16,000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: starting on day 1, 2.0 Gy fractions x 15 fractions given 5 days per week for 3 weeks; then 2.0 Gy fractions x 10 fractions x 2 weeks to the initial tumor length plus a 5 cm margin, for a total dose of 50.0 Gy.

'''11-week course of therapy'''

===Variant #2, 50.4 Gy {{#subobject:3272d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/5/1167.long Minsky et al. 2002 (RTOG 94-05)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin, 5-FU, high-dose RT
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70028-2/abstract Conroy et al. 2014 (PRODIGE5/ACCORD17)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#PRODIGE5.2FACCORD17|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#PRODIGE5.2FACCORD17|See link]]
|-
|}
''Patients: RTOG 94-05 included both adenocarcinoma and squamous cell histology''

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 30 minutes once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]] as follows:
**RTOG 94-05: 1.8 Gy fractions x 28 fractions given 5 days per week, starting on day 1, for a total dose of 50.4 Gy.
**PRODIGE5/ACCORD17: 2.0 Gy fractions x 25 fractions given 5 days per week, starting on day 1, for a total dose of 50 Gy.

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#Cisplatin_.26_Fluorouracil_2|CF consolidation]]

===Variant #3, 66 Gy {{#subobject:0d8520|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/10/1160.long Bedenne et al. 2007 (FFCD 9102)]
| style="background-color:#1a9851" |Phase III (E)
|Surgery
|style="background-color:#eeee01" |Equivalent OS
|-
|}
''Patients: 89% epidermoid, 11% glandular histology. Note that this was not a formal noninferiority study but the study met its primary endpoint of equivalence.''
====Preceding treatment====
*[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]] x 2
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 15 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 5
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 10 fractions given 5 days per week, for a total dose of 66 Gy (including the initial 46 Gy)
**Earlier in the study, some patients instead received split-course radiation therapy

====Supportive medications====
*1 liter NS IV over 2 hours before and after [[Cisplatin (Platinol)]]

'''21-day cycle for 1 cycle, then 28-day cycle for 2 cycles'''   

===References===
# '''RTOG 85-01:''' Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992 Jun 11;326(24):1593-8. [https://www.nejm.org/doi/full/10.1056/NEJM199206113262403 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1584260 PubMed]
## '''Update:''' al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997 Jan;15(1):277-84. [http://jco.ascopubs.org/content/15/1/277.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8996153 PubMed]
## '''Update:''' Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL; Radiation Therapy Oncology Group. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999 May 5;281(17):1623-7. [http://jama.jamanetwork.com/article.aspx?articleid=189737 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10235156 PubMed]
# '''RTOG 94-05:''' Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1;20(5):1167-74. [http://jco.ascopubs.org/content/20/5/1167.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11870157 PubMed]
# '''FFCD 9102:''' Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007 Apr 1;25(10):1160-8. [http://jco.ascopubs.org/content/25/10/1160.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17401004 PubMed]
# '''PRODIGE5/ACCORD17:''' Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70028-2/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24556041 PubMed]
## '''HRQoL analysis:''' Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer. 2017 Oct;84:239-249. Epub 2017 Aug 19. [https://www.ejcancer.com/article/S0959-8049(17)31158-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28829992 PubMed]

==Cisplatin, Paclitaxel, RT {{#subobject:5ef1ea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:8f0c89|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2643119 Suntharalingam et al. 2017 (RTOG 0436)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin, Paclitaxel, Cetuximab, RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
Patients: 62% ''adenocarcinoma, 38% squamous cell histology. 14% with M1a disease. 6% with Zubrod PS score 2.''

====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV once per week
*[[Paclitaxel (Taxol)]] 50 mg/m<sup>2</sup> IV once per week
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 28 fractions, for a total dose of 50.4 Gy

'''One course over 5 weeks'''

===References===
# '''RTOG 0436:''' Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: The NRG Oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol. 2017 Nov 1;3(11):1520-1528. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2643119 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28687830 PubMed]

==FOLFOX4 & RT {{#subobject:1f91c5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FOLFOX4 & RT: '''<u>FOL</u>'''inic acid, '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin, '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:e2fc30|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70028-2/abstract Conroy et al. 2014 (PRODIGE5/ACCORD17)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#PRODIGE5.2FACCORD17|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#PRODIGE5.2FACCORD17|See link]]
|-
|}
''Note: In contrast to the original reference, some guidelines list the dosage of leucovorin as 400 mg/m<sup>2</sup>. Despite being a non-superior experimental arm, this regimen is recommended by some guidelines such as ESMO.''
====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1600 mg/m<sup>2</sup> IV continuous infusion over 46 hours, '''given third''' (total dose per cycle: 2000 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 2 hours once on day 1
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 25 fractions given 5 days per week, for a total dose of 50 Gy 

'''14-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#FOLFOX4|FOLFOX4]] x 3

===References===
# '''PRODIGE5/ACCORD17:''' Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70028-2/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24556041 PubMed]
## '''HRQoL analysis:''' Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer. 2017 Oct;84:239-249. Epub 2017 Aug 19. [https://www.ejcancer.com/article/S0959-8049(17)31158-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28829992 PubMed]

==Radiation therapy==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199206113262403 Herskovic et al. 1992 (RTOG 85-01)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT_2|Cisplatin, 5-FU, RT]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''Patients: 88% squamous cell, 12% adenocarcinoma histology. 7% Karnofsky performance scale of 50-60''

''Radiation as primary therapy; used as a comparator arm and here for reference purposes only.''
====Radiotherapy====
*[[External beam radiotherapy]] total of 32 fractions in 6.4 weeks: 50 Gy of regional treatment and 14 Gy to the boost field, for total dose of 64 Gy

===References===
# '''RTOG 85-01:''' Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992 Jun 11;326(24):1593-8. [https://www.nejm.org/doi/full/10.1056/NEJM199206113262403 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1584260 PubMed]
## '''Update:''' al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997 Jan;15(1):277-84. [http://jco.ascopubs.org/content/15/1/277.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8996153 PubMed]
## '''Update:''' Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL; Radiation Therapy Oncology Group. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999 May 5;281(17):1623-7. [http://jama.jamanetwork.com/article.aspx?articleid=189737 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10235156 PubMed]

=Consolidation after definitive therapy=
==Cisplatin & Fluorouracil {{#subobject:cf23a6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF: '''<u>C</u>'''isplatin & '''<u>F</u>'''luorouracil
===Regimen {{#subobject:ade242|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/5/1167.long Minsky et al. 2002 (RTOG 94-05)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70028-2/abstract Conroy et al. 2014 (PRODIGE5/ACCORD17)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#PRODIGE5.2FACCORD17|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#PRODIGE5.2FACCORD17|See link]]
|-
|}
''Patients: study included both adenocarcinoma and squamous cell histology''
====Preceding treatment====
*RTOG 94-05: [[#Cisplatin.2C_Fluorouracil.2C_RT_2|Definitive CF & RT]] versus definitive CF & high-dose RT
*PRODIGE5/ACCORD17: [[#Cisplatin.2C_Fluorouracil.2C_RT_2|Definitive CF & RT]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 30 minutes once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''28-day cycle for 2 cycles'''

===References===
# '''RTOG 94-05:''' Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1;20(5):1167-74. [http://jco.ascopubs.org/content/20/5/1167.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11870157 PubMed]
# '''PRODIGE5/ACCORD17:''' Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70028-2/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24556041 PubMed]
## '''HRQoL analysis:''' Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer. 2017 Oct;84:239-249. Epub 2017 Aug 19. [https://www.ejcancer.com/article/S0959-8049(17)31158-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28829992 PubMed]

==FOLFOX4 {{#subobject:a8048e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FOLFOX4: '''<u>FOL</u>'''inic acid, '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin 4
===Regimen {{#subobject:f200f1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70028-2/abstract Conroy et al. 2014 (PRODIGE5/ACCORD17)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#PRODIGE5.2FACCORD17|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#PRODIGE5.2FACCORD17|See link]]
|-
|}
''Note: In contrast to the original reference, some guidelines list the dosage of leucovorin as 400 mg/m<sup>2</sup>. Despite being a non-superior experimental arm, this regimen is recommended by some guidelines such as ESMO.''
====Preceding treatment====
*[[#FOLFOX4_.26_RT|FOLFOX4 & RT]]

====Chemotherapy====
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1600 mg/m<sup>2</sup>/day IV continuous infusion over 46 hours, '''given third''' (total dose per cycle: 2000 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 2 hours once on day 1

'''14-day cycle for 3 cycles'''

===References===
# '''PRODIGE5/ACCORD17:''' Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70028-2/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24556041 PubMed]
## '''HRQoL analysis:''' Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer. 2017 Oct;84:239-249. Epub 2017 Aug 19. [https://www.ejcancer.com/article/S0959-8049(17)31158-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28829992 PubMed]

=Adjuvant therapy=
==5-FU & Leucovorin, then 5-FU, Leucovorin, RT, then 5-FU & Leucovorin {{#subobject:f6b345|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1 {{#subobject:5cd826|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa010187 Macdonald et al. 2001 (INT-0116)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Preceding treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]]
====Chemotherapy, part 1====
*[[Fluorouracil (5-FU)]] 425 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5 (total dose per cycle: 2125 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5

'''28-day cycle, followed by:'''

====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once per day on days 1 to 4 and the last 3 days of radiation therapy (total dose per cycle: 2800 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 4 and the last 3 days of radiation therapy
*Concurrent [[External_beam_radiotherapy|radiation therapy]] starting cycle 2 day 1 with 1.8 Gy, 5 days per week; 25 fractions given over 5 weeks for a total of 45 Gy

'''35-day cycle, followed by:'''

====Chemotherapy, part 2, to start one month after the completion of radiotherapy====
*[[Fluorouracil (5-FU)]] 425 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5 (total dose per cycle 2125 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5

'''28-day cycle for 2 cycles'''

===Variant #2 {{#subobject:c3cc1c|Variant=1}}===
''Note: No primary reference could be found for this regimen.''
====Preceding treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus on EITHER days 1 & 15 OR days 1, 2, 15, 16
*[[Fluorouracil (5-FU)]] 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 2, 15, 16 (total dose per cycle: 4800 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 400 mg/m<sup>2</sup> IV on EITHER days 1 & 15 OR days 1, 2, 15, 16

'''28-day cycle for 3 total cycles (1 cycle given before radiation, and 2 cycles to be given after radiation)'''

===References===
# '''INT-0116:''' Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30. [https://www.nejm.org/doi/full/10.1056/NEJMoa010187 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11547741 PubMed]

==Cisplatin & Fluorouracil {{#subobject:e35a6c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
<br>FP: '''<u>F</u>'''luorouracil, '''<u>P</u>'''latinol
===Variant #1, 75/5000 {{#subobject:fc3c70|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199812313392704 Kelsen et al. 1998 (RTOG 8911)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Cisplatin_.26_Fluorouracil|Neoadjuvant CF]], then [[Surgery#Esophageal_cancer_surgery|surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose per cycle: see note)

'''28-day cycle for 3 cycles'''

===Variant #2, 80/4000 {{#subobject:e4f654|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.12.095 Ando et al. 2003 (JCOG 9204)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#91cf60" |Seems to have superior DFS
|-
|[https://link.springer.com/article/10.1245%2Fs10434-011-2049-9 Ando et al. 2011 (JCOG 9907)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Fluorouracil|Neoadjuvant CF]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
====Preceding treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''21-day cycle for 2 cycles'''

===Variant #3, 100/4000 {{#subobject:d61794|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.0597 Ychou et al. 2011 (ACCORD 07)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Surgery_alone|Surgery alone]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''

''Patients: 100% adenocarcinoma histology (65% gastroesophageal junction, 10% lower esophageal, 25% gastric adenocarcinoma)'' 
====Preceding treatment====
*[[#Cisplatin_.26_Fluorouracil|Neoadjuvant CF]], then [[Surgery#Esophageal_cancer_surgery|surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''28-day cycle for 3 to 4 cycles for a total of 6 cycles'''

===References===
# '''RTOG 8911:''' Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31;339(27):1979-84. [https://www.nejm.org/doi/full/10.1056/NEJM199812313392704 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9869669 PubMed]
# '''JCOG 9204:''' Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H; Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol. 2003 Dec 15;21(24):4592-6. [http://ascopubs.org/doi/full/10.1200/JCO.2003.12.095 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14673047 PubMed]
# '''ACCORD 07:''' Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. Epub 2011 Mar 28. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.0597 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21444866 PubMed]
# '''JCOG 9907:''' Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012 Jan;19(1):68-74. Epub 2011 Aug 31. [https://link.springer.com/article/10.1245%2Fs10434-011-2049-9 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21879261 PubMed]

==Cisplatin & Irinotecan {{#subobject:308dd0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:507e9f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563156/ Yoon et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% adenocarcinoma of the esophagus or gastroesophageal junction (tumor extension < 2cm into gastric cardia)''

====Preceding treatment====
*[[#Cisplatin.2C_Irinotecan.2C_RT|Neoadjuvant cisplatin, irinotecan, RT]], then [[Surgery#Esophageal_cancer_surgery|surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Irinotecan (Camptosar)]] 65 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 3 cycles'''

===References===
# Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011 Oct;68(4):863-70. Epub 2011 Feb 1. [http://www.springerlink.com/content/v4g0257025185531/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563156/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21286719 PubMed]

==Cisplatin & Paclitaxel {{#subobject:b40afb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c15e56|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563156/ Yoon et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% adenocarcinoma of the esophagus or gastroesophageal junction (tumor extension < 2cm into gastric cardia)''

====Preceding treatment====
*[[#Cisplatin.2C_Paclitaxel.2C_RT|Neoadjuvant cisplatin, paclitaxel, RT]], then [[Surgery#Esophageal_cancer_surgery|surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''

===References===
# Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011 Oct;68(4):863-70. Epub 2011 Feb 1. [http://www.springerlink.com/content/v4g0257025185531/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563156/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21286719 PubMed]

==ECF {{#subobject:87a09a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:d40982|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055531 Cunningham et al. 2006 (MAGIC)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#MAGIC|See link]]
|[[Complex_multipart_regimens#MAGIC|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 Al-Batran et al. 2017 (FLOT4-AIO)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|-
|}
''This is the adjuvant portion of pre-planned perioperative chemotherapy.''

''Cunningham et al. Patients: 100% adenocarcinoma histology (75% gastric adenocarcinoma, 15% lower esophagus, 11% gastroesophageal junction).''

''Al-Batran et. al Patients: 100% adenocarcinoma histology of the gastroesophageal junction (AEG I-III) or the stomach.''

====Preceding treatment====
*[[#ECF|Neoadjuvant ECF]] x 3, then [[Surgery#Esophageal_cancer_surgery|surgery]]
====Chemotherapy, to start 6 to 12 weeks after surgery====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>)

====Supportive medications====
*MAGIC: [[Warfarin (Coumadin)]] 1 mg PO once per day recommended for thrombosis prophylaxis

'''21-day cycle for 3 cycles'''

===References===
# '''MAGIC:''' Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa055531 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16822992 PubMed]
# '''Abstract:''' Salah-Eddin Al-Batran, Nils Homann, Harald Schmalenberg, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Wolff H. Schmiegel, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Peter C. Thuss-Patience, Wolfgang Fischbach, Jorg Trojan, Michael Koenigsmann, Claudia Pauligk, Thorsten Oliver Goetze, Elke Jaeger, Johannes Meiler, Martin H. Schuler, and Ralf Hofheinz. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 link to abstract]

==ECF, then 5-FU & RT, then ECF {{#subobject:7f3e93|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECF, then 5-FU & RT, then ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil, followed by '''<u>5</u>'''-'''<u>F</u>'''luoro'''<u>U</u>'''racil & '''<u>R</u>'''adiation '''<u>T</u>'''herapy, followed by '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:53c380|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.redjournal.org/article/S0360-3016(09)03613-X/abstract Leong et al. 2010]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the primary reference, some guidelines list this regimen without ECF cycles 1, 3, 4.''

''Patients: 100% adenocarcinoma (6% gastroesophageal junction, 94% gastric origin).''
====Preceding treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]], within 10 weeks
====Chemotherapy, part 1====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose: 4200 mg/m<sup>2</sup>)

'''21-day cycle, followed 1 to 3 weeks later by:'''

====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]] 225 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose: 7875 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week for a total dose of 45 Gy, starting on day 1

'''5-week course, followed 1 month later by:'''

====Chemotherapy, part 2====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>)

'''21-day cycle for 2 cycles'''

===References===
# Leong T, Joon DL, Willis D, Jayamoham J, Spry N, Harvey J, Di Iulio J, Milner A, Mann GB, Michael M. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):690-5. Epub 2010 May 14. [http://www.redjournal.org/article/S0360-3016(09)03613-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20472363 PubMed]

==ECX {{#subobject:c8ab0e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECX: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
===Regimen {{#subobject:27f848|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30043-8/fulltext Cunningham et al. 2017 (UK MRC ST03)]
| style="background-color:#1a9851" |Phase III (C)
|ECX & Bevacizumab
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 Al-Batran et al. 2017 (FLOT4-AIO)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|-
|}
''This is the adjuvant portion of pre-planned perioperative chemotherapy.''

''Cunningham et al. Patients: 100% adenocarcinoma histology (36% gastric, 14% lower esophageal, 50% gastroesophageal junction).''

''Al-Batran et al.'' ''Patients: 100% adenocarcinoma histology including gastroesophageal junction (AEG I-III) or the stomach.''

====Preceding treatment====
*[[#ECX|Neoadjuvant ECX]] x 3, then [[Surgery#Esophageal_cancer_surgery|surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21

'''21-day cycle for 3 cycles'''

===References===
# '''UK MRC ST03:''' Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol. 2017 Mar;18(3):357-370. Epub 2017 Feb 3. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30043-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337626/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28163000 PubMed]
# '''Abstract:''' Salah-Eddin Al-Batran, Nils Homann, Harald Schmalenberg, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Wolff H. Schmiegel, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Peter C. Thuss-Patience, Wolfgang Fischbach, Jorg Trojan, Michael Koenigsmann, Claudia Pauligk, Thorsten Oliver Goetze, Elke Jaeger, Johannes Meiler, Martin H. Schuler, and Ralf Hofheinz. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 link to abstract]

==FLOT {{#subobject:3ad093|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FLOT: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>O</u>'''xaliplatin, '''<u>T</u>'''axotere (Docetaxel)
===Regimen {{#subobject:e6d646|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 Al-Batran et al. 2017 (FLOT4-AIO)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#FLOT4-AIO|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#FLOT4-AIO|See link]]
|-
|}
''This is the adjuvant portion of pre-planned perioperative chemotherapy.''

''Patients: 100% adenocarcinoma histology including gastroesophageal junction (AEG I-III) or the stomach.''
====Preceding treatment====
*[[#FLOT|Neoadjuvant FLOT]] x 4, then [[Surgery#Esophageal_cancer_surgery|surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once on day 1

'''14-day cycle for 4 cycles'''

===References===
# '''Abstract:''' Salah-Eddin Al-Batran, Nils Homann, Harald Schmalenberg, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Wolff H. Schmiegel, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Peter C. Thuss-Patience, Wolfgang Fischbach, Jorg Trojan, Michael Koenigsmann, Claudia Pauligk, Thorsten Oliver Goetze, Elke Jaeger, Johannes Meiler, Martin H. Schuler, and Ralf Hofheinz. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 link to abstract]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.jtcvs.org/article/S0022-5223(97)70146-6/fulltext Ando et al. 1997 (JCOG8806)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin & Vindesine
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa010187 Macdonald et al. 2001 (INT-0116)]
| style="background-color:#1a9851" |Phase III (C)
|[[#5-FU_.26_Leucovorin.2C_then_5-FU.2C_Leucovorin.2C_RT.2C_then_5-FU_.26_Leucovorin|5-FU & Leucovorin, then 5-FU, Leucovorin, RT, then 5-FU & Leucovorin]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055531 Cunningham et al. 2006 (MAGIC)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#MAGIC|Perioperative ECF]]
| style="background-color:#d73027" |Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.0597 Ychou et al. 2011 (ACCORD 07)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#ACCORD_07|Perioperative CF]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''Surgery as primary therapy; i.e., no induction chemotherapy or chemoradiotherapy, and no adjuvant therapy.''

''McDonald et al. patients: 100% adenocarcinoma histology, originating from the stomach or gastroesophageal junction.'' 
''MAGIC patients: 100% adenocarcinoma of the stomach or lower third of the esophagus. 74% gastric, 15% lower esophagus, 11% gastroesophageal  junction.''

====Preceding treatment====
*[[Surgery#Esophageal_cancer_surgery|Surgery]]

===References===
# '''JCOG8806:''' Ando N, Iizuka T, Kakegawa T, Isono K, Watanabe H, Ide H, Tanaka O, Shinoda M, Takiyama W, Arimori M, Ishida K, Tsugane S. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg. 1997 Aug;114(2):205-9. [https://www.jtcvs.org/article/S0022-5223(97)70146-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9270637 PubMed]
# '''INT-0116:''' Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30. [https://www.nejm.org/doi/full/10.1056/NEJMoa010187 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11547741 PubMed]
# '''MAGIC:''' Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa055531 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16822992 PubMed]
# '''ACCORD 07:''' Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. Epub 2011 Mar 28. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.0597 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21444866 PubMed]

=Metastatic or locally advanced disease (non-radiation/surgery candidate)=

==CapeOx {{#subobject:c699c3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CapeOx: '''<u>Cape</u>'''citabine and '''<u>Ox</u>'''aliplatin
===Regimen {{#subobject:d1aac0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.62.6598 Hecht et al. 2015 (LOGiC)]
| style="background-color:#1a9851" |Phase III (C)
|CapeOx & Lapatinib
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''100% adenocarcinoma histology (4% esophagus, 9% gastroesophageal junction, 87% gastric origin). 9% with ECOG PS of 2.'' 
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 850 mg/m<sup>2</sup> PO twice per day on days 1 to 14 
*[[Oxaliplatin (Eloxatin)]] 130 mg/m2 IV on day 1

'''21-day cycle for up to 8 cycles'''

===References===
# Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houé V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC--a randomized phase III trial. J Clin Oncol. 2016 Feb 10;34(5):443-51. Epub 2015 Nov 30. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.6598 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26628478 PubMed]

==CAPIRI {{#subobject:c699c3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CapeIRI: '''<u>Cape</u>'''citabine and '''<u>IRI</u>'''notecan
<br>CAPIRI: '''<u>CAP</u>'''ecitabine and '''<u>IRI</u>'''notecan
<br>XELIRI: '''<u>XEL</u>'''ox (Capecitabine) and '''<u>IRI</u>'''notecan
<br>XI: '''<u>X</u>'''eloda (Capecitabine) and '''<u>I</u>'''rinotecan
===Regimen {{#subobject:d233c0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.springerlink.com/content/8051q1q431p22662/ Leary et al. 2008]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdp269 Moehler et al. 2009]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#CX_2|XP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients: 45% esophageal, 38% gastroesophageal  junction, 17% gastric origin. 93% adenocarcinoma, 7% squamous cell histology. 86% metastatic disease. 14% ECOG PS of 2.'' 

====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Irinotecan (Camptosar)]] 250 mg/m<sup>2</sup> IV over 30 to 90 minutes once on day 1

====Supportive medications====
*[[Atropine (Atropen)]] 0.25 mg SC before [[Irinotecan (Camptosar)]] as prophylaxis against cholinergic symptoms 
*[[Loperamide (Imodium)]] 4 mg PO prn first unformed stool, then 2 mg PO Q2H x at least 12 hours, or for 12 hours after last liquid stool
*[[Ciprofloxacin (Cipro)]] 250 mg PO twice per day prn diarrhea lasting longer than 24 hours despite loperamide
 
'''21-day cycle for up to 8 cycles (Leary et al. 2008) or indefinitely (Moehler et al. 2009)'''

===References===
# Leary A, Assersohn L, Cunningham D, Norman AR, Chong G, Brown G, Ross PJ, Costello C, Higgins L, Oates J. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol. 2009 Aug;64(3):455-62. Epub 2008 Dec 23. [http://www.springerlink.com/content/8051q1q431p22662/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19104814 PubMed]
# Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR, Hoehler T; Arbeitsgemeinschaft Internistische Onkologie. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2010 Jan;21(1):71-7. Epub 2009 Jul 15. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdp269 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19605504 PubMed]

==Carboplatin & Paclitaxel {{#subobject:4df570|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9725d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/9427274 Philip et al. 1997]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the original reference, some guidelines list the dosage of carboplatin as AUC 6.''

''Philip et al. Patients: locally advanced metastatic or recurrent esophageal or gastric cancer'' 
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycles'''

===References===
# Philip PA, Zalupski MM, Gadgeel S, Hussain M, Shields A. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-86-S19-88. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9427274 PubMed]

==Carboplatin, Docetaxel, Fluorouracil {{#subobject:f4e05b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e0e534|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=53&abstractID=10199 Elkerm et al. 2008]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: this study does not appear to have been published as a manuscript, and the abstract link no longer works.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 2
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1200 mg/m<sup>2</sup>/day IV continuous infusion over 48 hours, started on day 1 (total dose per cycle: 2400 mg/m<sup>2</sup>)

====Supportive medications====
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 4 to 9

'''21-day cycles'''

===References===
# '''Abstract:''' Y. M. Elkerm, A. Elsaid, S. AL-Batran, C. Pauligk. Final results of a phase II trial of docetaxel-carboplatin-FU in locally advanced gastric carcinoma. 2008 Gastrointestinal Cancers Symposium abstract 38. [http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=53&abstractID=10199 link to abstract]

==Cetuximab monotherapy {{#subobject:5aca6d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b11ea0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928397 Gold et al. 2010 (SWOG S0415)]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% metastatic esophageal adenocarcinoma who failed one prior chemotherapy regimen. 10% had ECOG PS of 2.'' 

====Chemotherapy====
*[[Cetuximab (Erbitux)]] as follows:
**Cycle 1: 400 mg/m<sup>2</sup> IV over 2 hours on day 1, then 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 8, 15, 22
**Cycle 2 onwards: 250 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 50 mg IV or PO 30 to 60 minutes prior to cetuximab

'''28-day cycles'''

===References===
# Gold PJ, Goldman B, Iqbal S, Leichman LP, Zhang W, Lenz HJ, Blanke CD. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol. 2010 Sep;5(9):1472-6. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928397 link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928397/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20631636 PubMed]

==Cisplatin & Docetaxel {{#subobject:724868|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DC: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin
<br>TC: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''isplatin
===Variant #1 {{#subobject:f1913d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/24/5660.long Ajani et al. 2005 (V-325)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#DCF|DCF]]
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|}
''Patients: 100% adenocarcinoma histology (32% gastroesophageal junction/fundus and 68% gastric antrum/body). 95% were metastatic. 1% with Karnofsky PS score of 70.'' 

====Chemotherapy====
*[[Docetaxel (Taxotere)]] 85 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO the night before chemotherapy, the morning of day 1, 1 hour before chemotherapy, the night of day 1, the morning of day 2, and the evening of day 2 (6 total doses)
*[[Dexamethasone (Decadron)]] 20 mg IV before [[Cisplatin (Platinol)]] and 8 hours after [[Cisplatin (Platinol)]]
*[[Ondansetron (Zofran)]] 8 mg IV before [[Cisplatin (Platinol)]], 4 hours after [[Cisplatin (Platinol)]], and 8 hours after [[Cisplatin (Platinol)]]
*"Hydration was administered in a standard manner"

'''21-day cycles'''

===Variant #2 {{#subobject:6adc30|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.springerlink.com/content/e131402311p276x0/ Kim et al. 2009]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% squamous cell histology. 5% with ECOG PS of 2.'' 

====Chemotherapy====
*[[Docetaxel (Taxotere)]] 70 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given 3 hours before cisplatin'''
*[[Cisplatin (Platinol)]] 70 mg/m<sup>2</sup> IV over 60 minutes once on day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO twice per day x 1 day, starting 1 day before [[Docetaxel (Taxotere)]] administration
*At least 3 liters hydration (with mannitol, magnesium, and potassium chloride)
*"Antiemetic treatment"

'''21-day cycle for up to 6 cycles'''

===References===
# '''V-325:''' Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660-7. [http://jco.ascopubs.org/content/23/24/5660.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16110025 PubMed]
# Kim JY, Do YR, Park KU, Kim MK, Lee KH, Bae SH, Ryoo HM, Baek JH, Song HS. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol. 2010 May;66(1):31-6. Epub 2009 Sep 18. [http://www.springerlink.com/content/e131402311p276x0/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19763571 PubMed]

==Cisplatin & Fluorouracil {{#subobject:4d9936|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
<br>FP: '''<u>F</u>'''luorouracil, '''<u>P</u>'''latinol
===Variant #1 {{#subobject:10f0c6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/31/4991.long Van Cutsem et al. 2006 (V325 Study Group)]
| style="background-color:#1a9851" |Phase III (C)
|[[#DCF|DCF]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://annonc.oxfordjournals.org/content/19/8/1450.long Dank et al. 2008]
| style="background-color:#1a9851" |Phase III (C)
|[[#FOLFIRI|IF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Van Cutsem et al Patients: 100% adenocarcinoma histology (22% gastroesophageal junction, 88% gastric origin). 97% with metastatic disease. 1% with Karnosky PS of 70.'' 

''Dank et al Patients: 100% adenocarcinoma histology (20% gastroesophageal junction, 80% gastric origin). 96% with metastatic disease. 1% with Karnofsky PS of 70.'' 

====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given first'''
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 5000 mg/m<sup>2</sup> )

====Supportive medications====
*As described in Dank et al. 2008:
*"Hyperhydration" for 2 to 3 days with each infusion
*[[Ondansetron (Zofran)]] IV for antiemetic prophylaxis
*[[Dexamethasone (Decadron)]] IV for antiemetic prophylaxis, then PO for 2 to 3 days
*[[Metoclopramide (Reglan)]] for antiemetic prophylaxis
*[[Filgrastim (Neupogen)]] (dose not specified) SC once per day, starting on day 4, to be continued until ANC greater than 1000/uL for grade 3 to 4 neutropenia, febrile neutropenia, or neutropenic infection
*[[Atropine (Atropen)]] prn cholinergic symptoms 
*[[Loperamide (Imodium)]] prn delayed diarrhea

'''28-day cycles'''

===Variant #2 {{#subobject:fe6c13|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/20/10/1667.long Lorenzen et al. 2009]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Cisplatin.2C_Fluorouracil.2C_Cetuximab|CF & Cetuximab]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients: 100% squamous cell histology. 87% with metastatic disease. No patients with ECOG PS greater than 1.''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 5000 mg/m<sup>2</sup> )

====Supportive medications====
*"Standard antiemetic prophylaxis and pre- and post- [[Cisplatin (Platinol)]] hydration"

'''29-day cycle for up to 6 cycles'''

===Variant #3 {{#subobject:782e95|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext Bang et al. 2010 (ToGA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#CF_.26_Trastuzumab|CF & Trastuzumab]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''Patients in '''ToGA''' had overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation.''

''ToGA Patients: 100% adenocarcinoma (19% gastroesophageal junction, 81% gastric). 10% with ECOG of 2.'' 
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

====Supportive medications====
*"Hyperhydration" for [[Cisplatin (Platinol)]]

'''21-day cycle for up to 6 cycles'''

===References===
# '''V325 Study Group:''' Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. [http://jco.ascopubs.org/content/24/31/4991.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17075117 PubMed]
# Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7. Epub 2008 Jun 16. [http://annonc.oxfordjournals.org/content/19/8/1450.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18558665 PubMed]
# Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009 Oct;20(10):1667-73. Epub 2009 Jun 23. [http://annonc.oxfordjournals.org/content/20/10/1667.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19549707 PubMed]
# '''ToGA:''' Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20728210 PubMed]

==Cisplatin, Fluorouracil, Cetuximab {{#subobject:717dc4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF-C: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil, '''<u>C</u>'''etuximab
===Regimen {{#subobject:54b7fe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/20/10/1667.long Lorenzen et al. 2009]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Cisplatin_.26_Fluorouracil_4|CF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients: 100% squamous cell histology. 87% with metastatic disease. No patients with ECOG PS greater than 1.''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup> )
*[[Cetuximab (Erbitux)]] as follows:
**Cycle 1: 400 mg/m<sup>2</sup> IV over 2 hours once on day 1, then 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 8, 15, 22
**Cycles 2 to 6: 250 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

====Supportive medications====
*"Standard antiemetic prophylaxis and pre- and post- [[Cisplatin (Platinol)]] hydration"

'''29-day cycle for up to 6 cycles'''

===References===
# Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009 Oct;20(10):1667-73. Epub 2009 Jun 23. [http://annonc.oxfordjournals.org/content/20/10/1667.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19549707 PubMed]

==CF & Trastuzumab {{#subobject:ca9cd1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil

===Regimen {{#subobject:b2731|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext Bang et al. 2010 (ToGA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Fluorouracil_4|CF]]
| style="background-color:#1a9850" |Superior OS
|-
|}
''Patients had overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation.''

''Patients: 100% adenocarcinoma (19% gastroesophageal junction, 81% gastric). 10% with ECOG of 2.'' 
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Subsequent cycles: 6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20728210 PubMed]

==Cisplatin, Doxorubicin liposomal, Fluorouracil {{#subobject:f31fcc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1b58a0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.springerlink.com/content/n8477v3g21081103 Cascinu et al. 2010]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#MCF|MCF]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Patients: 11% gastroesophageal junction, 89% gastric origin. 90% metastatic. 6% with ECOG PS of 2.'' 

====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Pegylated liposomal doxorubicin (Doxil)]] 20 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup> IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m<sup>2</sup> )

'''14-day cycles'''

===References===
# Cascinu S, Galizia E, Labianca R, Ferraù F, Pucci F, Silva RR, Luppi G, Beretta GD, Berardi R, Scartozzi M. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemother Pharmacol. 2011 Jul;68(1):37-43. Epub 2010 Sep 7. [http://www.springerlink.com/content/n8477v3g21081103/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20821330 PubMed]

==Cisplatin & Irinotecan {{#subobject:ec60da|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CI: '''<u>C</u>'''isplatin & '''<u>I</u>'''rinotecan
===Variant #1 {{#subobject:8f624d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.cancernetwork.com/esophageal-cancer/phase-ii-trial-weekly-irinotecancisplatin-advanced-esophageal-cancer Ilson 2004]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the original reference, some guidelines list cisplatin 25 mg/m<sup>2</sup> as an alternate dosage.''

''Patients: 26% squamous cell, 74% adenocarcinoma histology. 85% metastatic disease.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Irinotecan (Camptosar)]] 65 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''

===Variant #2 {{#subobject:219a1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/17/10/3270.full Ilson et al. 1999]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 66% adenocarcinoma, 34% squamous cell histology. Did not receive any prior chemotherapy. 97% with metastatic disease.'' 

====Chemotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV bolus once per day on days 1, 8, 15, 22
*[[Irinotecan (Camptosar)]] 65 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV prior to chemotherapy
*[[Granisetron]] 2 mg PO prior to chemotherapy
*At least 500 mL D5NS IV over 30 to 60 minutes before [[Cisplatin (Platinol)]]
*[[Atropine (Atropen)]] used as pretreatment medication if there was diarrhea or abdominal cramps within 1 hour of [[Irinotecan (Camptosar)]]

'''42-day cycles''' 

===References===
# Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999 Oct;17(10):3270-5. [http://jco.ascopubs.org/content/17/10/3270.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10506629 PubMed]
# Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):22-5. [http://www.cancernetwork.com/esophageal-cancer/phase-ii-trial-weekly-irinotecancisplatin-advanced-esophageal-cancer link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15685830 PubMed]

==Cisplatin & Paclitaxel {{#subobject:5d50ee|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:c401a9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2008&issue=02000&article=00005&type=abstract Zhang et al. 2008]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% squamous cell carcinoma with advanced or metastatic disease. 18% ECOG PS of 2.''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #2 {{#subobject:ffaa05|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/11079171 Ilson et al. 2000]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the original reference, some guidelines list the paclitaxel dose as 135 mg/m<sup>2</sup>. No primary reference could be found for the 135 mg/m<sup>2</sup> dosage. The protocol reported here was amended to change the original dose of 250 mg/m<sup>2</sup> to 200 mg/m<sup>2</sup> based on toxicity and treatment-related deaths.''

''Patients: 87% adenocarcinoma, 13% squamous cell histology. Included both gastroesophageal junction and esophageal patients. 95% with metastatic disease. None had received prior chemotherapy.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 2, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

====Supportive medications====
*"Granulocyte colony stimulating factor support"

'''21-day cycles'''

===Variant #3 {{#subobject:a5b523|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063082 Petrasch et al. 1998]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 25% adenocarcinoma, 75% squamous cell histology. Consisting of unresectable stage III disease, recurrent or metastatic tumors of esophageal origin.'' 

====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 90 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Cimetidine (Tagamet)]] 300 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Clemastine (Tavist)]] 2 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Ondansetron (Zofran)]] 8 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*"Adequate pre- and posthydration" for [[Cisplatin (Platinol)]]

'''14-day cycles'''

===References===
# Petrasch S, Welt A, Reinacher A, Graeven U, König M, Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer. 1998 Aug;78(4):511-4. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063082 link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063082/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/9716036 PubMed]
# Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, Kelsen DP. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J. 2000 Sep-Oct;6(5):316-23. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11079171 PubMed]
# Zhang X, Shen L, Li J, Li Y, Li J, Jin M. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol. 2008 Feb;31(1):29 to 33. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2008&issue=02000&article=00005&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18376224 PubMed]

==CX {{#subobject:c58325|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CX: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
<br>XP: '''<u>X</u>'''eloda (Capecitabine), '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:130681|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdp269 Moehler et al. 2009]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#CAPIRI|XI]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext Bang et al. 2010 (ToGA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#CX_.26_Trastuzumab|CX & Trastuzumab]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70102-5/abstract Lordick et al. 2013 (EXPAND)]
| style="background-color:#1a9851" |Phase III (C)
|[[#CX_.26_Cetuximab|CX & Cetuximab]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients in '''ToGA''' had overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation. Patients:100% adenocarcinoma (19% gastroesophageal junction, 81% gastric). 10% with ECOG of 2.'' 

''Lordick Patients: 100% adenocarcinoma (stomach or gastroesophageal junction) locally advanced unresectable (M0) or metastatic (M1).''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
**Lordick et al. 2013 gave [[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day from the evening of day 1 to the morning of day 15 (28 doses per cycle)

====Supportive medications====
*per Kang et al. 2009:
*"Hyperhydration" for [[Cisplatin (Platinol)]]

'''21-day cycles'''

===References===
# Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR, Hoehler T; Arbeitsgemeinschaft Internistische Onkologie. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2010 Jan;21(1):71-7. Epub 2009 Jul 15. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdp269 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19605504 PubMed]
# '''ToGA:''' Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20728210 PubMed]
# '''EXPAND:''' Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie (AIO) and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):490-9. Epub 2013 Apr 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70102-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23594786 PubMed]

==CX-C {{#subobject:318959|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CX-C: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine), '''<u>C</u>'''etuximab
===Regimen {{#subobject:afe6a1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70102-5/abstract Lordick et al. 2013 (EXPAND)]
| style="background-color:#1a9851" |Phase III (E)
|[[#CX_2|CX]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Lordick Patients: 100% adenocarcinoma (stomach or gastroesophageal junction) locally advanced unresectable (M0) or metastatic (M1).''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day from the evening of day 1 to the morning of day 15 (28 doses per cycle)
*[[Cetuximab (Erbitux)]] as follows:
**Cycle 1: 400 mg/m<sup>2</sup> IV once on day 1
**Subsequently: 250 mg/m<sup>2</sup> IV once per week

'''21-day cycles'''

===References===
# Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie (AIO) and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):490-9. Epub 2013 Apr 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70102-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23594786 PubMed]

==CX & Trastuzumab {{#subobject:7cbb79|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CX: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
===Variant #1 {{#subobject:cdee6d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.6852 Shah et al. 2017 (HELOISE)]
| style="background-color:#1a9851" |Phase IIIb (C)
|CX & HD-Trastuzumab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients had overexpression of HER2 protein by immunohistochemistry AND gene amplification by in-situ hybridisation. Patients: 100% metastatic adenocarcinoma (gastroesophageal junction or gastric)''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 800 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Subsequent cycles: 6 mg/kg IV once on day 1

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Trastuzumab alone continued indefinitely

===Variant #2 {{#subobject:27adc6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext Bang et al. 2010 (ToGA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#CX_2|CX]]
| style="background-color:#1a9850" |Superior OS
|-
|}
''Patients had overexpression of HER2 protein by immunohistochemistry OR gene amplification by fluorescence in-situ hybridisation. Patients: 100% adenocarcinoma (19% gastroesophageal junction, 81% gastric). 10% with ECOG of 2.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Subsequent cycles: 6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20728210 PubMed]
# Shah MA, Xu RH, Bang YJ, Hoff PM, Liu T, Herráez-Baranda LA, Xia F, Garg A, Shing M, Tabernero J. HELOISE: Phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2017 Aug 1;35(22):2558-2567. Epub 2017 Jun 2. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.6852 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28574779 PubMed]

==Docetaxel monotherapy {{#subobject:421f5e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 75 mg/m<sup>2</sup> {{#subobject:044193|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://annonc.oxfordjournals.org/content/24/6/1567.long Roy et al. 2013]
| style="background-color:#1a9851" |Randomized Phase II (C)
|1. [[#Irinotecan_monotherapy|Irinotecan]]<br> 2. [[#Irinotecan_liposomal_monotherapy|Irinotecan liposomal]]
|style="background-color:#d3d3d3" |Not powered to draw conclusions
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70549-7/fulltext Ford et al. 2013 (COUGAR-02)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Active symptom control]]
| style="background-color:#1a9850" |Superior OS
|-
|}
''COUGAR-02 patients: 100% adenocarcinoma histology  (20% esophageal, 35% gastroesophageal'' ''junction, 45% stomach) that progressed on or within 6 months of treatment with a platinum-fluoropyrimidine combination. 15% ECOG PS of 2. 12% locally advanced, 88% metastatic disease.'' 

====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycle for up to 6 cycles (COUGAR-02) or indefinitely (Roy et al. 2013)'''

===Variant #2, 100 mg/m<sup>2</sup> {{#subobject:b279a5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://link.springer.com/article/10.1007/s12032-007-0028-6 Albertsson et al. 2007]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: squamous cell or adenocarcinoma histology of the esophagus or gastric cardia.''

====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycles'''

===References===
# Albertsson M, Johansson B, Friesland S, Kadar L, Letocha H, Frykholm G, Wagenius G. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol. 2007;24(4):407-12. [http://link.springer.com/article/10.1007/s12032-007-0028-6 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17917090 PubMed]
# Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. [https://annonc.oxfordjournals.org/content/24/6/1567.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23406728 PubMed]
# '''COUGAR-02:''' Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86. Epub 2013 Dec 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70549-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24332238 PubMed]

==DCF {{#subobject:efbdc5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DCF: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
<br>TCF: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil

===Variant #1 {{#subobject:5aba07|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/24/5660.long Ajani et al. 2005 (V-325)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Cisplatin_.26_Docetaxel_2|DC]]
| style="background-color:#91cf60" |Seems to have superior ORR
|-
|[http://jco.ascopubs.org/content/24/31/4991.long Van Cutsem et al. 2006 (V325 Study Group)]
| style="background-color:#1a9851" |Phase III (E)
|[[#CF|CF]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}

''Note: In contrast to the original references, some guidelines list each cycle as lasting 28 days.''

''Anjani et al. Patients: 100% adenocarcinoma histology (32% gastroesophageal junction/fundus and 68% gastric antrum/body). 95% were metastatic. 1% with Karnofsky PS score of 70.'' 

''Van Cutsem et al Patients: 100% adenocarcinoma histology (22% gastroesophageal junction, 88% gastric origin). 97% with metastatic disease. 1% with Karnosky PS score of 70.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m<sup>2</sup>)

====Supportive medications====
*(varied depending on reference):
*[[Dexamethasone (Decadron)]] 8 mg PO the night before chemotherapy, the morning of day 1, 1 hour before chemotherapy, the night of day 1, the morning of day 2, and the evening of day 2 (6 total doses)
*[[Dexamethasone (Decadron)]] 20 mg IV before [[Cisplatin (Platinol)]] and 8 hours after [[Cisplatin (Platinol)]]
*[[Ondansetron (Zofran)]] 8 mg IV before [[Cisplatin (Platinol)]], 4 hours after [[Cisplatin (Platinol)]], and 8 hours after [[Cisplatin (Platinol)]]
*"Hydration [was] administered in a standard manner"

'''21-day cycles'''

===Variant #2 {{#subobject:baa015|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/25/22/3217.long Roth et al. 2007]
| rowspan="2" style="background-color:#1a9851" |Randomized Phase II (E)
|1. [[#ECF_2|ECF]]
| style="background-color:#d3d3d3" |Not reported
|-
|2. [[#Cisplatin_.26_Docetaxel_2|TC]]
| style="background-color:#d9ef8b" |Might have superior ORR
|-
|}
''Note: the protocol was amended to change the original dose of ''docetaxel from'' 85 mg/m<sup>2</sup> to 75 mg/m<sup>2</sup> based on high incidence of febrile neutropenia.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 4 hours once on day 1
*[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion over 14 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>)

====Supportive medications====
*3 liters per day "hyperhydration"
*[[Dexamethasone (Decadron)]] 8 mg PO given 12 hours & 6 hours before [[Docetaxel (Taxotere)]], then 8 mg PO twice per day for 4 days after [[Docetaxel (Taxotere)]]
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis
*Growth factor support allowed, such as with [[Filgrastim (Neupogen)]]

'''21-day cycle for up to 8 cycles'''

===References===
# '''V-325:''' Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660-7. [http://jco.ascopubs.org/content/23/24/5660.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16110025 PubMed]
# '''V325 Study Group:''' Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. [http://jco.ascopubs.org/content/24/31/4991.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17075117 PubMed]
# Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. [http://jco.ascopubs.org/content/25/22/3217.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17664469 PubMed]

==mDCF {{#subobject:70e20f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
mDCF: '''<u>m</u>'''odified '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Variant #1 {{#subobject:323b13|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://meetinglibrary.asco.org/content/1882-72 Ozal et al. 2010]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3000 mg/m<sup>2</sup>)

'''21-day cycles'''

===Variant #2 {{#subobject:372f9c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646322/ Shah et al. 2010]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the primary reference, some guidelines list this regimen without bevacizumab. Please see below for the original mDCF regimen that included bevacizumab.''

''Patients: 100% adenocarcinoma (50% gastric, 45% gastroesophageal junction, 5% esophagus). 93% received no prior therapy.'' 
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 15, 29
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV over 1 to 3 hours once per day on days 3, 17, 31
*[[Folinic acid (Leucovorin)]] 400 mg/m<sup>2</sup> IV once per day on days 1, 15, 29
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once per day on days 1, 15, 29, then 2400 mg/m<sup>2</sup> IV continuous infusion over 48 hours, started after each bolus (total dose per cycle: 7200 mg/m<sup>2</sup>)

====Supportive medications====
*"Standard premedication and delayed emesis regimens"

'''42-day cycles'''

===References===
# '''Abstract:''' G. Ozal, M. Dogan, H. Akbulut, B. Yalcin, G. Utkan, Y. Urun, F. Icli. The safety and efficacy of modified-dose docetaxel, cisplatin, and 5-fluorouracil (mDCF) combination in the front-line treatment of advanced gastric cancer. 2010 Gastrointestinal Cancers Symposium abstract 113. [http://meetinglibrary.asco.org/content/1882-72 link to abstract]
# Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011 Mar 1;29(7):868-74. Epub 2010 Dec 28. [http://jco.ascopubs.org/content/29/7/868.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646322/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21189380 PubMed]

==mDCF & Bevacizumab {{#subobject:30ea9e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
mDCF: '''<u>m</u>'''odified '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:5485f9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646322/ Shah et al. 2010]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% adenocarcinoma (50% gastric, 45% gastroesophageal junction, 5% esophagus). 93% received no prior therapy.''

====Chemotherapy====
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 15, 29
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV over 1 to 3 hours once per day on days 3, 17, 31
*[[Folinic acid (Leucovorin)]] 400 mg/m<sup>2</sup> IV once per day on days 1, 15, 29
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once per day on days 1, 15, 29, then 2400 mg/m<sup>2</sup> IV continuous infusion over 48 hours, started after each bolus (total dose per cycle: 7200 mg/m<sup>2</sup>)
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1, 15, 29

====Supportive medications====
*"Standard premedication and delayed emesis regimens"

'''42-day cycles'''

===References===
# Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011 Mar 1;29(7):868-74. Epub 2010 Dec 28. [http://jco.ascopubs.org/content/29/7/868.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646322/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21189380 PubMed]

==Docetaxel & Irinotecan {{#subobject:96e013|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:38cdd0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699385/ Burtness et al. 2009]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 79% adenocarcinoma, 21% squamous cell histology. All patients ECOG PS of 0 or 1, and unresectable/metastatic disease.''

====Chemotherapy====
*[[Docetaxel (Taxotere)]] 35 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8, '''given first'''
*[[Irinotecan (Camptosar)]] 50 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8, '''given second'''

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO given 12 hours before [[Docetaxel (Taxotere)]], then 10 mg IV within 1 hour before chemotherapy. Then 8 mg PO given 12 hour afters chemotherapy.
*5-HT3 antagonist antiemetic IV given within 1 hour before chemotherapy 
*"Oral antiemetic therapy prescribed"
*Loperamide as needed

'''21-day cycles'''

===References===
# Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol. 2009 Jul;20(7):1242-8. Epub 2009 May 8. [http://annonc.oxfordjournals.org/content/20/7/1242.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699385/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19429872 PubMed]

==DOF {{#subobject:6e7c57|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DOF: '''<u>D</u>'''ocetaxel, '''<u>O</u>'''xaliplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:2e0f55|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10246 Shankaran et al. 2009]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1200 mg/m<sup>2</sup>/day IV continuous infusion over 46 hours, started on day 1 (total dose: 2400 mg/m<sup>2</sup>)

'''14-day cycles'''

===References===
# '''Abstract:''' V. Shankaran, M. F. Mulcahy, H. S. Hochster, T. Ryan, H. Choi, A. B. Benson. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: Preliminary results of a phase II study. 2009 Gastrointestinal Cancers Symposium abstract 47. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10246 link to abstract]

==ECF {{#subobject:6325cb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:e5ede0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/8/1996.long Ross et al. 2002]
| style="background-color:#1a9851" |Phase III (C)
|[[#MCF|MCF]]
| style="background-color:#eeee01" |Seems to have noninferior OS
|-
| rowspan="3" |[https://www.nejm.org/doi/full/10.1056/NEJMoa073149 Cunningham et al. 2008 (REAL-2)]
| style="background-color:#1a9851" rowspan="3" |Phase III (C)
|1. [[#ECX_2|ECX]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|2. [[#EOF_2|EOF]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|3. [[#EOX_2|EOX]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}

''Ross et al. Patients: adenocarcinoma, squamous carcinoma, or undifferentiated carcinoma histology, all advanced esophagogastric cancer.''

''REAL-2 Patients: 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2.'' 

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 4 hours once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>)

====Supportive medications====
*(varied depending on reference):
*3 liters per day "hyperhydration"
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis
*Growth factor support allowed, such as with [[Filgrastim (Neupogen)]]
*[[Warfarin (Coumadin)]] 1 mg PO once per day for catheter thrombosis prophylaxis

'''21-day cycle for up to 8 cycles'''

===References===
# Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002 Apr 15;20(8):1996-2004. [http://jco.ascopubs.org/content/20/8/1996.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11956258 PubMed]
# '''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https://www.nejm.org/doi/full/10.1056/NEJMoa073149 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18172173 PubMed]

==ECX {{#subobject:bb95b5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECX: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
===Variant #1, 50/60/625 {{#subobject:e965c5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa073149 Cunningham et al. 2008 (REAL-2)]
| style="background-color:#1a9851" rowspan="2" |Phase III (E)
|1. [[#ECF_2|ECF]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|2. [[#EOF_2|EOF]]<br> 3. [[#EOX_2|EOX]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70023-3/fulltext Iveson et al. 2014]
| style="background-color:#1a9851" |Randomized Phase II (C)
|ECX & Rilotumumab
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|}
''REAL-2 patients: 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2.''

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 4 hours once on day 1
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21

'''21-day cycle for up to 8 cycles (REAL-2) or indefinitely (Iveson et al. 2014)'''

===Variant #2, 50/60/1000 {{#subobject:2f83d2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2013.54.1011 Guimbaud et al. 2014 (FFCD 03-07)]
| style="background-color:#1a9851" |Phase III (C)
|[[#FOLFIRI|FOLFIRI]]
| style="background-color:#d73027" |Inferior TTF
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV over 15 minutes once on day 1
**Maximum cumulative dose allowed was 900 mg/m<sup>2</sup>
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 2 to 15

'''21-day cycles'''

===References===
# '''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https://www.nejm.org/doi/full/10.1056/NEJMoa073149 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18172173 PubMed]
# Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014 Aug;15(9):1007-18. Epub 2014 Jun 22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70023-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24965569 PubMed]
# '''FFCD 03-07:''' Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouché O. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014 Nov 1;32(31):3520-6. Epub 2014 Oct 6. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.1011 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25287828 PubMed]

==EOF {{#subobject:a6390c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EOF: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:abf19f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa073149 Cunningham et al. 2008 (REAL-2)]
| style="background-color:#1a9851" rowspan="2" |Phase III (E)
|1. [[#ECF_2|ECF]]<br> 2. [[#ECX_2|ECX]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|3. [[#EOX_2|EOX]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
''Patients: 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2.''

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>)

====Supportive medications====
*[[Warfarin (Coumadin)]] 1 mg PO once per day for catheter thrombosis prophylaxis

'''21-day cycle for up to 8 cycles'''

===References===
# '''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https://www.nejm.org/doi/full/10.1056/NEJMoa073149 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18172173 PubMed]

==EOX {{#subobject:438182|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EOX: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>X</u>'''eloda (Capecitabine)
<br>EOC: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>C</u>'''apecitabine
===Variant #1 {{#subobject:339609|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669518/ Waddell et al. 2013 (REAL3)]
| style="background-color:#1a9851" |Phase III (C)
|mEOC+P
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Patients: 99% adenocarcinoma, 1% undifferentiated histology. 39% esophagus, 31% ''gastroesophageal'' junction, 30% gastric. 6% ECOF PS of 2. 89% metastatic disease.'' 

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup>/day PO (it is assumed this daily dose was divided into two doses per day) on days 1 to 21

'''21-day cycle for up to 8 cycles'''

===Variant #2 {{#subobject:3e4f2b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="3" |[https://www.nejm.org/doi/full/10.1056/NEJMoa073149 Cunningham et al. 2008 (REAL-2)]
| style="background-color:#1a9851" rowspan="3" |Phase III (E)
|1. [[#ECF_2|ECF]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|2. [[#ECX_2|ECX]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|3. [[#EOF_2|EOF]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
''Patients: 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2.''

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day on days 1 to 21

'''21-day cycle for up to 8 cycles'''

===References===
# '''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https://www.nejm.org/doi/full/10.1056/NEJMoa073149 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18172173 PubMed] content property of [http://hemonc.org HemOnc.org]
# '''REAL3:''' Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):481-9. Epub 2013 Apr 15. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669518/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23594787 PubMed]

==Erlotinib monotherapy {{#subobject:5efb4d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:eaf7de|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/30/4922.long Dragovich et al. 2006 (SWOG 0127)]
| style="background-color:#91cf61" |Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116987/ Ilson et al. 2010]
| style="background-color:#91cf61" |Phase II
|-
|}
''Dragovich et al. Patients: 100% adenocarcinoma (63% gastroesophageal junction, 37% gastric origin). All with ECOG PS of 0 or 1.'' 

''Ilson et al. Patients: 57% adenocarcinoma, 43% squamous cell histology. 6% proximal esophagus, 35% distal esophagus, 59% gastroesophageal junction.'' 

====Chemotherapy====
*[[Erlotinib (Tarceva)]] 150 mg PO once per day on days 1 to 28, at least 1 hour before a meal, or 2 hours after a meal

'''28-day cycles'''

===References===
# Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006 Oct 20;24(30):4922-7. [http://jco.ascopubs.org/content/24/30/4922.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17050876 PubMed]
# Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2011 Apr 1;117(7):1409-14. Epub 2010 Nov 8. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.25602/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116987/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21425140 PubMed]

==Etoposide monotherapy {{#subobject:344c29|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bdcf31|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://link.springer.com/article/10.1007%2FBF00685952 Harstrick et al. 1992]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: this is higher than the dose usually employed in modern settings.''

''Patients: metastatic 100% squamous cell carcinoma of the esophagus, with ECOG PS range 1-2.''
====Chemotherapy====
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> (route not specified) once per day on days 1 to 3

'''21-day cycles'''

===References===
# Harstrick A, Bokemeyer C, Preusser P, Köhne-Wömpner CH, Meyer HJ, Stahl M, Knipp H, Schmoll HJ, Wilke H. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol. 1992;29(4):321-2. [https://link.springer.com/article/10.1007%2FBF00685952 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1537080 PubMed]

==Fluorouracil & Folinic acid {{#subobject:5aad1e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2d601|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/21/4319.long Bouché et al. 2004 (FFCD 9803)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|1. [[#CLF_2|LV5FU2 & Cisplatin]]<br> 2. [[#FOLFIRI|LV5FU2 & Irinotecan]]
| style="background-color:#d3d3d3" |Not powered to draw conclusions
|-
|}
''Note: the primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more typical schedule was used.''

''Patients: 100% adenocarcinoma (70% gastric origin, 30% cardia)''

====Chemotherapy====
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup>/day IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m<sup>2</sup>)

'''14-day cycle for at least 4 cycles'''

===References===
# '''FFCD 9803:''' Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. [http://jco.ascopubs.org/content/22/21/4319.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15514373 PubMed]

==Fluorouracil, Folinic acid, Gemcitabine {{#subobject:876cd7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:173a91|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.karger.com/Article/Abstract/87815 Morgan-Meadows et al. 2005]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% esophageal cancer (both squamous and adenocarcinoma histology). Patients received no prior therapy.'' 

====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1, 8, 15  (total dose per cycle: 1800 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===References===
<!-- # Michelle Pipp, Daniel Mulkerin, Deb Warren, Wesley Hotchkis, Jordan Berlin, James P Thomas. A Phase II Trial of Gemcitabine and 5-Fluoruracil in Advanced Esophageal Cancer. 2001 ASCO Annual Meeting abstract 630. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=10&abstractID=630 link to abstract] -->
# Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP. A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology. 2005;69(2):130-4. Epub 2005 Aug 23. [http://www.karger.com/Article/Abstract/87815 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16118509 PubMed]

==FLOT {{#subobject:b427b1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FLOT: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>O</u>'''xaliplatin, '''<u>T</u>'''axotere (Docetaxel)
===Regimen {{#subobject:bb5eb6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/19/11/1882.long Al-Batran et al. 2008]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% adenocarcinoma histology (44% gastroesophageal junction, 56% gastric origin). 93% metastatic disease. 15% with ECOG 2-3.''

====Chemotherapy====
*[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1, '''given fourth'''
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV over 1 to 2 hours once on day 1
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 1 to 2 hours once on day 1
*[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV over 1 to 2 hours once on day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO once per day on days 0 to 3 of every cycle

'''14-day cycle for up to 8 (or more) cycles'''

===References===
# Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008 Nov;19(11):1882-7. Epub 2008 Jul 31. [http://annonc.oxfordjournals.org/content/19/11/1882.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18669868 PubMed]

==FOLFIRI {{#subobject:ba35aa|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FOLFIRI: '''<u>FOL</u>'''inic acid, '''<u>F</u>'''luorouracil, '''<u>IRI</u>'''notecan
<br>IF: '''<u>I</u>'''rinotecan & 5-'''<u>F</u>'''luorouracil
===Variant #1, 6 out of 7 weeks ("AIO regimen") {{#subobject:cec083|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/19/8/1450.long Dank et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|[[#CF|CF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://journals.lww.com/anti-cancerdrugs/pages/articleviewer.aspx?year=2009&issue=03000&article=00002&type=abstract Wolff et al. 2009]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Patients: 100% adenocarcinoma histology (20% gastroesophageal junction, 80% gastric origin). 96% with metastatic disease.'' 

====Chemotherapy====
*[[Fluorouracil (5-FU)]] 2000 mg/m<sup>2</sup>/day IV continuous infusion over 22 hours, started on days 1, 8, 15, 22, 29, 36, '''given third''' (total dose per cycle: 12,000 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 500 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36, '''given second'''
*[[Irinotecan (Camptosar)]] 80 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, '''given first'''

====Supportive medications====
*[[Ondansetron (Zofran)]] for antiemetic prophylaxis
*[[Dexamethasone (Decadron)]] for antiemetic prophylaxis
*[[Filgrastim (Neupogen)]] (dose not specified) SC once per day, starting on day 4, to be continued until ANC greater than 1000/uL for grade 3 to 4 neutropenia, febrile neutropenia, or neutropenic infection
*[[Atropine (Atropen)]] prn cholinergic symptoms 
*[[Loperamide (Imodium)]] prn delayed diarrhea

'''7-week cycles'''

===Variant #2, LV5FU2 & Irinotecan (200/1600/180) {{#subobject:56018a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/21/4319.long Bouché et al. 2004 (FFCD 9803)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|1. [[#Fluorouracil_.26_Folinic_acid|LV5FU2]]<br> 2. [[#CLF_2|LV5FU2 & Cisplatin]]
| style="background-color:#d3d3d3" |Not powered to draw conclusions
|-
|}
''Patients: 100% adenocarcinoma (70% gastric origin, 30% cardia).'' 

''Note: the primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more typical schedule was used.''
====Chemotherapy====
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup> IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m<sup>2</sup>)
*[[Irinotecan (Camptosar)]] 180 mg/m<sup>2</sup> IV over 90 minutes once on day 1

'''14-day cycle for at least 4 cycles'''

===Variant #3, 400/2800/180 {{#subobject:6526d0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2013.54.1011 Guimbaud et al. 2014 (FFCD 03-07)]
| style="background-color:#1a9851" |Phase III (E)
|[[#ECX_3|ECX]]
| style="background-color:#1a9850" |Superior TTF
|-
|}
====Chemotherapy====
*[[Folinic acid (Leucovorin)]] 400 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours, '''given third''' (total dose per cycle: 2800 mg/m<sup>2</sup>)
*[[Irinotecan (Camptosar)]] 180 mg/m<sup>2</sup> IV over 90 minutes once on day 1

'''14-day cycles''' 

===References===
# '''FFCD 9803:''' Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. [http://jco.ascopubs.org/content/22/21/4319.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15514373 PubMed]
# Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7. Epub 2008 Jun 16. [http://annonc.oxfordjournals.org/content/19/8/1450.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18558665 PubMed]
# Wolff K, Wein A, Reulbach U, Männlein G, Brückl V, Meier C, Ostermeier N, Schwab SA, Horbach T, Hohenberger W, Hahn EG, Boxberger F. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs. 2009 Mar;20(3):165-73. [http://journals.lww.com/anti-cancerdrugs/pages/articleviewer.aspx?year=2009&issue=03000&article=00002&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19125117 PubMed]
# '''Retrospective:''' Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R, Bécouarn Y, Desseigne F, Edeline J, Mitry E, Bouché O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):48-54. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21634054 PubMed]
# '''FFCD 03-07:''' Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouché O. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014 Nov 1;32(31):3520-6. Epub 2014 Oct 6. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.1011 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25287828 PubMed]

==mFOLFOX6 & Cetuximab {{#subobject:e51095|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
mFOLFOX6 & Cetuximab: '''<u>m</u>'''odified '''<u>FOL</u>'''inic acid, '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin, Cetuximab
<br>FOLFOX-C: '''<u>FOL</u>'''inic acid, '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin, '''<u>C</u>'''etuximab
===Regimen {{#subobject:2a9d10|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019745/ Enziger et al. 2016 (CALGB 80403/ECOG E1206)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|1. ECF-C<br> 2. IC-C
| style="background-color:#d3d3d3" |Not powered to draw conclusions
|-
|}
''Patients: 91% adenocarcinoma, 9% squamous cell histology. 56% esophageal, 43% gastroesophageal tumors.'' 

''To receive full-dose therapy in this trial, patients were required to have an absolute neutrophil count of 1,000/µL or greater, platelets of 75,000/µL or greater, and no other grade 2 or higher treatment-related toxicity.''

====Chemotherapy====
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 to 48 hours, '''given third''' (total dose per cycle: 2800 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 400 mg/m<sup>2</sup> IV over 2 hours once on day 1, '''given second, with oxaliplatin'''
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 2 hours once on day 1, '''given second, with leucovorin'''
*[[Cetuximab (Erbitux)]] 400 mg/m<sup>2</sup> IV over 2 hours once on day 1 of the first cycle and then 250 mg/m<sup>2</sup> IV over 60 minutes once per week, '''given first'''

'''14-day cycles'''

===References===
<!--
# P. C. Enzinger, B. Burtness, D. Hollis, D. Niedzwiecki, D. Ilson, A. B. Benson, R. J. Mayer, R. M. Goldberg. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. 2010 ASCO Annual Meeting abstract 4006. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=44487 link to abstract] -->
# '''CALGB 80403/ECOG E1206:''' Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol. 2016 Aug 10;34(23):2736-42. Epub 2016 Jul 5. [http://jco.ascopubs.org/content/34/23/2736.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019745/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27382098 PubMed]

==Irinotecan monotherapy {{#subobject:6df2c0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 21-day cycles {{#subobject:9b9808|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://annonc.oxfordjournals.org/content/24/6/1567.long Roy et al. 2013]
| style="background-color:#1a9851" |Randomized Phase II (C)
|1. [[#Docetaxel_monotherapy|Docetaxel]]<br> 2. [[#Irinotecan_liposomal_monotherapy|Irinotecan liposomal]]
|style="background-color:#d3d3d3" |Not powered to draw conclusions
|-
|}
====Chemotherapy====
*[[Irinotecan (Camptosar)]] 300 mg/m<sup>2</sup> IV over 90 minutes once on day 1

'''21-day cycles'''

===Variant #2, 4 out of 6 weeks {{#subobject:9fb427|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://link.springer.de/link/service/journals/00384/contents/02/00464/ Mühr-Wilkenshoff et al. 2003]
| style="background-color:#ffffbe" |Phase II, <20 patients
|-
|[http://link.springer.com/article/10.1007%2Fs10620-005-3038-2 Enzinger et al. 2005]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the primary references, some guidelines list a dosing schedule of 125 mg/m<sup>2</sup> IV once per day on days 1 & 8, with 21-day cycles.''

''Muhr-Wilkenshoff patients: Ten with esophageal squamous cell carcinoma,  three with esophageal adenocarcinoma''

''Enzinger patients: 100% adenocarcinoma histology, both gastric and esophageal''

====Chemotherapy====
*[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 60 minutes (Mühr-Wilkenshoff et al. 2003) or 90 minutes (Enzinger et al. 2005) once per day on days 1, 8, 15, 22

'''42-day cycles'''

===References===
# Mühr-Wilkenshoff F, Hinkelbein W, Ohnesorge I, Wolf KJ, Riecken EO, Zeitz M, Scherübl H. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis. 2003 Jul;18(4):330-4. Epub 2003 Feb 1. [http://link.springer.de/link/service/journals/00384/contents/02/00464/ link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12774248 PubMed]
# Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec;50(12):2218-23. [http://link.springer.com/article/10.1007%2Fs10620-005-3038-2 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16416165 PubMed]
# Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. [https://annonc.oxfordjournals.org/content/24/6/1567.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23406728 PubMed]

==Irinotecan liposomal monotherapy {{#subobject:9a99c8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c50e15|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://annonc.oxfordjournals.org/content/24/6/1567.long Roy et al. 2013]
| style="background-color:#1a9851" |Randomized Phase II (E)
|1. [[#Docetaxel_monotherapy|Docetaxel]]<br> 2. [[#Irinotecan_monotherapy|Irinotecan]]
|style="background-color:#d3d3d3" |Not powered to draw conclusions
|-
|}
====Chemotherapy====
*[[Irinotecan liposome (Onivyde)]] 120 mg/m<sup>2</sup> IV over 90 minutes once on day 1

'''21-day cycles'''

===References===
# Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. [https://annonc.oxfordjournals.org/content/24/6/1567.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23406728 PubMed]

==Irinotecan & Mitomycin {{#subobject:dfc95f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:87100a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|Comparator
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641556/ Lustberg et al. 2010]
| style="background-color:#1a9851" |Randomized Phase II (E)
|Irinotecan & Mitomycin (alternate schedule)
|-
|}
''Patients: 56% lower esophageal, 44% gastroesophageal junction. 100% adenocarcinoma histology. 100% previously untreated 6% with ecog OF 2. 77% stage four disease.''  

====Chemotherapy====
*[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV once per day on days 2 & 9
*[[Mitomycin (Mutamycin)]] 6 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Ondansetron (Zofran)]] or [[Granisetron]] and [[Dexamethasone (Decadron)]] premedication
*[[Loperamide (Imodium)]] started with first episode of diarrhea
*Erythropoietin for hemoglobin less than 10 g/dL permitted

'''28-day cycle for up to 6 cycles'''

===Variant #2 {{#subobject:4a905|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2005&issue=12000&article=00009&type=abstract Giuliani et al. 2005]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% gastric adenocarcinoma. Treatment given as second-line chemotherapy for pretreated patients with advanced or metastatic disease.'' 

====Chemotherapy====
*[[Irinotecan (Camptosar)]] 150 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Mitomycin (Mutamycin)]] 8 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles'''
 
===Variant #3 {{#subobject:3213a7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.jchemother.it/cgi-bin/digisuite.exe/product?ID=252&IDCategory=30 Bamias et al. 2003]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: Advanced gastric and colorectal cancers. All previously received 5-fluorouracil-based chemotherapy.''

====Chemotherapy====
*[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV once on day 1
*[[Mitomycin (Mutamycin)]] 5 mg/m<sup>2</sup> IV once on day 1

'''14-day cycles'''

===References===
# Bamias A, Papamichael D, Syrigos K, Pavlidis N. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. J Chemother. 2003 Jun;15(3):275-81. [http://www.jchemother.it/cgi-bin/digisuite.exe/product?ID=252&IDCategory=30 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12868555 PubMed]
# Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, Vinciarelli G, Gebbia N, Colucci G; Gruppo Oncologico dell' Italia Meridionale. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot 2106). Am J Clin Oncol. 2005 Dec;28(6):581-5. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2005&issue=12000&article=00009&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16317268 PubMed]
# Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol. 2010 May;5(5):713-8. [https://www.jto.org/article/S1556-0864(15)32147-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641556/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20354452 PubMed]

==MCF {{#subobject:d3775b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MCF: '''<u>M</u>'''itomycin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:47b99f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/8/1996.long Ross et al. 2002]
| style="background-color:#1a9851" |Phase III (E)
|[[#ECF_2|ECF]]
| style="background-color:#eeee01" |Seems to have noninferior OS
|-
|[http://www.springerlink.com/content/n8477v3g21081103 Cascinu et al. 2010]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Cisplatin.2C_Doxorubicin_liposomal.2C_Fluorouracil|Cisplatin, Doxorubicin liposomal, Fluorouracil]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''Cascinu Patients: 11% gastroesophageal junction, 89% gastric origin. 90% metastatic. 6% with ECOG PS of 2.'' 

====Chemotherapy====
*[[Mitomycin (Mutamycin)]] 7 mg/m<sup>2</sup> (maximum dose of 14 mg) IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once per day on days 1 & 22
*[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion, started on day 1 (total dose per cycle: 12,600 mg/m<sup>2</sup>)

====Supportive medications====
*[[Warfarin (Coumadin)]] 1 mg PO once per day for catheter thrombosis prophylaxis

'''42-day cycle for up to 6 months'''

===References===
# Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002 Apr 15;20(8):1996-2004. [http://jco.ascopubs.org/content/20/8/1996.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11956258 PubMed]
# Cascinu S, Galizia E, Labianca R, Ferraù F, Pucci F, Silva RR, Luppi G, Beretta GD, Berardi R, Scartozzi M. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemother Pharmacol. 2011 Jul;68(1):37-43. Epub 2010 Sep 7. [http://www.springerlink.com/content/n8477v3g21081103/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20821330 PubMed]

==Paclitaxel monotherapy {{#subobject:ed008a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, weekly {{#subobject:dd30a4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/18/5/898.long Ilson et al. 2007]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients: 100% esophageal cancers. 66% adenocarcinoma, 34% squamous cell. Median ECOG PS 1, ranging 0-2.'' 

====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV 30 to 60 minutes before paclitaxel
*[[Cimetidine (Tagamet)]] 300 mg IV 30 to 60 minutes prior to paclitaxel 
*[[Diphenhydramine (Benadryl)]] 50 mg IV 30 to 60 minutes prior to paclitaxel 

'''28-day cycles'''

===Variant #2, CI {{#subobject:1d24a4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jnci.oxfordjournals.org/content/86/14/1086.long Ajani et al. 1994]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the original reference, some guidelines list the dosage of paclitaxel as 135 to 175 mg/m<sup>2</sup>.''

''Patients: 100% esophageal cancer. 36% squamous cell, 64% adenocarcinoma histology.''

====Chemotherapy====
*[[Paclitaxel (Taxol)]] 250 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
**Dosage adjusted based on toxicity down to 150 or 200 mg/m<sup>2</sup>, or up to 280 mg/m<sup>2</sup>

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg PO 14 hours and 7 hours before paclitaxel
*[[Cimetidine (Tagamet)]] 300 mg IV 60 minutes prior to paclitaxel 
*[[Diphenhydramine (Benadryl)]] 50 mg IV 60 minutes prior to paclitaxel 
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting 24 hours after the paclitaxel infusion finishes

'''21-day cycles'''

===References===
# Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994 Jul 20;86(14):1086-91. [http://jnci.oxfordjournals.org/content/86/14/1086.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7912736 PubMed]
# Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 2007 May;18(5):898-902. Epub 2007 Mar 9. [http://annonc.oxfordjournals.org/content/18/5/898.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17351256 PubMed]
# '''RAINBOW:''' Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970420-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25240821 PubMed]

==Paclitaxel & Ramucirumab {{#subobject:fdd93f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f66446|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Overall response rate|'''ORR''']]
!Comparator [[Overall response rate|'''ORR''']]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970420-6/fulltext Wilke et al. 2014 (RAINBOW)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy|Paclitaxel]]
| style="background-color:#91cf60" |Seems to have superior OS
|28% (95% CI 23-33%)
|16% (95% CI 13-20%)
|-
|}
''Eligibility criteria for patients in RAINBOW included: "documented objective radiological or clinical disease progression during or within 4 months of the last dose of first-line platinum and fluoropyrimidine doublet with or without anthracycline."''

''Patients: 100% adenocarcinoma histology, 20% gastroesophageal junction, 80% gastric origin.'' 

====Chemotherapy====
*[[Ramucirumab (Cyramza)]] 8 mg/kg IV once per day on days 1 & 15
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# '''RAINBOW:''' Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970420-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25240821 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961719-5/fulltext Fuchs et al. 2013 (REGARD)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Ramucirumab_monotherapy|Ramucirumab]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70549-7/fulltext Ford et al. 2013 (COUGAR-02)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_monotherapy|Docetaxel]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70024-5/fulltext Dutton et al. 2014 (COG)]
| style="background-color:#1a9851" |Phase III (C)
|Gefitinib
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/34/13/1448.full Li et al. 2016]
| style="background-color:#1a9851" |Phase III (C)
|Apatinib
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''Patients in REGARD previously had "disease progression within 4 months of the last dose of first-line platinum-containing or fluoropyrimidine-containing chemotherapy for metastatic disease, or within 6 months of the last dose of platinum-containing or fluoropyrimidine-containing adjuvant treatment."''

''No active antineoplastic treatment. Used as a comparator arm and here for reference purposes only.''

''Fuchs patients: 100% adenocarcinoma histology (25% gastroesophageal junction, 75% gastric origin).''  

''Ford patients: 100% adenocarcinoma histology (20% esophageal, 35% esophagogastric junction, 45% stomach) that progressed on or within 6 months of treatment with a platinum-fluoropyrimidine combination. 15% ECOG PS of 2. 12% locally advanced, 88% metastatic disease.'' 

''Dutton patients: 24% squamous cell, 76% adenocarcinoma histology. 78% esophageal, 22% gastroesophageal junction''

''Li patients: 100% adenocarcinoma histology (70% gastric origin, 22% gastroesophageal junction, 8% unknown). All patients with at least two prior lines of treatment.''

===References===
# '''REGARD:''' Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Epub 2013 Oct 3. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961719-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24094768 PubMed]
# '''COUGAR-02:''' Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86. Epub 2013 Dec 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70549-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24332238 PubMed]
# '''COG:''' Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk S, Garcia-Alonso A, Fyfe DW, Hubner RA, Gamble T, Peachey L, Davoudianfar M, Pearson SR, Julier P, Jankowski J, Kerr R, Petty RD. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014 Jul;15(8):894-904. Epub 2014 Jun 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70024-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24950987 PubMed]
# Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016 May 1;34(13):1448-54. Epub 2016 Feb 16. [http://jco.ascopubs.org/content/34/13/1448.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26884585 PubMed]

==Ramucirumab monotherapy {{#subobject:425b15|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:813cff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Overall response rate|'''ORR''']]
!Comparator [[Overall response rate|'''ORR''']]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961719-5/fulltext Fuchs et al. 2013 (REGARD)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#91cf60" |Seems to have superior OS
|3%
|3%
|-
|}
''Patients in REGARD previously had "disease progression within 4 months of the last dose of first-line platinum-containing or fluoropyrimidine-containing chemotherapy for metastatic disease, or within 6 months of the last dose of platinum-containing or fluoropyrimidine-containing adjuvant treatment."''

''Patients: 100% adenocarcinoma histology (25% gastroesophageal junction, 75% gastric origin)''

====Chemotherapy====
*[[Ramucirumab (Cyramza)]] 8 mg/kg IV once every 2 weeks

'''Continued indefinitely'''

===References===
# '''REGARD:''' Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Epub 2013 Oct 3. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961719-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24094768 PubMed]

[[Category:Esophageal cancer regimens]]
[[Category:Disease-specific pages]]
[[Category:Gastrointestinal cancers]]
